🏷

Classifications

Harrison's Part

🔗

Mappings

MONDO

MONDO:0013897 Loeys-Dietz syndrome 4

MONDO models Loeys-Dietz syndrome 4 as the TGFB2-caused subtype of Loeys-Dietz syndrome (MONDO:0018954), asserting TGFB2 (HGNC:11768) as the causal gene via RO:0004003 and carrying the OMIM:614816 cross-reference. This entry curates exactly that concept.

📘

Definitions

1

Molecular and clinical diagnosis of LDS4

The diagnosis of Loeys-Dietz syndrome is established by identification of a heterozygous pathogenic variant in one of the six Loeys-Dietz genes in a proband with aortic root enlargement, type A dissection, or other characteristic clinical features. LDS4 is the designation applied when that gene is TGFB2. Because the cardiovascular phenotype in TGFB2 families is milder and later-onset than in TGFBR1/TGFBR2 disease, and because non-penetrance is comparatively common, molecular testing rather than the clinical aortic threshold is frequently what establishes the diagnosis.

DIAGNOSTIC_CRITERIA

Show evidence (3 references)

PMID:20301312 SUPPORT Human Clinical

"by the identification of a heterozygous pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2 or biallelic pathogenic variants in IPO8 in a proband with aortic root enlargement, type A dissection, other characteristic clinical features of LDS, or a family history of an established..."

GeneReviews states the molecular diagnostic criterion for Loeys-Dietz syndrome, naming TGFB2 among the causal genes.

PMID:29392890 SUPPORT Human Clinical

"patients with mutations in TGFB2 share clinical manifestations with LDS, and are for this reason now diagnosed with LDS type 4 (LDS4)"

Establishes that the LDS4 designation is defined by the causal gene being TGFB2, which is the concept MONDO:0013897 models.

PMID:36832261 SUPPORT Human Clinical

"To date, six subtypes of LDS are currently described."

Confirms the six-subtype molecular partition of Loeys-Dietz syndrome within which LDS4 is the TGFB2 subtype.

👪

Inheritance

1

Autosomal dominant inheritance HP:0000006

LDS4 is inherited in an autosomal dominant manner. Heterozygous TGFB2 loss-of-function variants segregate with thoracic aortic disease in large multigenerational pedigrees, and whole-gene deletions at 1q41 produce the same phenotype through haploinsufficiency. Penetrance is incomplete and expressivity is highly variable even within a single family: reduced penetrance is more common in TGFB2 families than in the receptor-related Loeys-Dietz subtypes, so an obligate carrier may be entirely unaffected. This is the key practical consequence of the genetics - cascade testing, not clinical screening alone, is what identifies at-risk relatives. Transmission risk follows directly: each child of an affected individual has a 50% chance of inheriting the variant, roughly three quarters of Loeys-Dietz probands carry a de novo variant while roughly one quarter have an affected parent, and once the familial variant is known prenatal and preimplantation genetic testing are available.

Autosomal dominant inheritance

Show evidence (7 references)

PMID:20301312 SUPPORT Human Clinical

"LDS caused by a pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2 is inherited in an autosomal dominant manner."

GeneReviews states autosomal dominant inheritance for the TGFB2-related subtype among the other Loeys-Dietz genes.

PMID:22772371 SUPPORT Human Clinical

"These mutations-a frameshift mutation in exon 6 and a nonsense mutation in exon 4-segregated with disease with a combined logarithm of odds (LOD) score of 7.7."

Quantifies the dominant segregation of TGFB2 loss-of-function alleles with thoracic aortic disease in two large unrelated families.

PMID:29392890 SUPPORT Human Clinical

"Non‐penetrance seems more common in TGFB2/3 families."

Qualifies the dominant inheritance: penetrance is reduced relative to the TGFBR1/2 subtypes, which is why apparently sporadic presentations and clinically unaffected obligate carriers recur in TGFB2 families.

+ 4 more references

◈

Mechanistic Hypotheses

2

Compensatory ligand overshoot (canonical model of the TGF-beta paradox)

compensatory_ligand_overshoot CANONICAL

Evidence balance 2 support

The canonical reconciliation of the LDS4 paradox. Loss of one TGFB2 allele lowers cellular TGF-beta 2; the aortic wall responds with autocrine and/or paracrine compensation - increased expression of TGF-beta 2 itself and a shift towards TGF-beta 1 - that overshoots, producing a net high-TGF-beta tissue signature (nuclear pSMAD2, CTGF) in the diseased aorta. Under this model the sequence is decrease first, secondary increase second, and it is the secondary excess that drives medial degeneration. Both 2012 defining papers converge on it, and the Tgfb2+/- mouse reproduces the same increase in canonical and non-canonical signalling.

Pathograph links

Reduced TGF-beta 2 Ligand Availability -> Paradoxical Aortic TGF-beta Signaling Dysregulation Reduced cellular TGF-beta 2 provokes a compensatory response in the aortic wall that overshoots into excess TGF-beta signalling.

Show evidence (2 references)

PMID:22772371 SUPPORT Human Clinical

"the initial pathway driving disease is decreased cellular TGF-β2 levels leading to a secondary increase in TGF-β2 production in the diseased aorta"

States the two-step model exactly: cellular decrease first, aortic compensatory increase second.

PMID:22772368 SUPPORT Model Organism

"these data support the hypothesis that compensatory autocrine and/or paracrine events contribute to the pathogenesis of TGF-β-mediated vasculopathies"

Names the compensatory autocrine/paracrine mechanism this hypothesis group encodes, on the strength of the Tgfb2+/- and Fbn1/Tgfb2 double mutant mouse data.

TGFBR3-dependent aortic root smooth muscle differentiation defect

tgfbr3_smc_differentiation EMERGING

Evidence balance 2 support

An emerging, developmentally framed alternative that does not require the paradox to be resolved at all. TGFB2 signal transduction in smooth muscle cells is distinctively TGFBR3 (betaglycan)-dependent, and the TGFB2-TGFBR3 axis is enriched in the aortic root tunica media. Under this model, TGFB2 haploinsufficiency impairs the differentiation of second heart field-derived smooth muscle cells that build the root, yielding a regionally deficient media - which would explain both the root-predominant distribution of LDS4 aneurysm and, through redundancy among the TGF-beta isoforms, its milder aggressiveness compared with receptor-gene disease. The evidence is entirely from a human iPSC/CRISPR system; it has not been shown in patient aortic tissue, so this is recorded as EMERGING rather than as a competitor to the canonical model.

Pathograph links

Reduced TGF-beta 2 Ligand Availability -> Impaired Aortic Root Smooth Muscle Cell Differentiation TGF-beta 2 is required, via TGFBR3, for differentiation of the second heart field-derived smooth muscle cells that populate the aortic root.

Show evidence (2 references)

PMID:40139558 SUPPORT In Vitro

"siRNA experiments revealed that TGFB2 distinctively displays TGFBR3 dependence for signal transduction, an understudied TGFβ receptor in TAAD"

Establishes the TGFBR3 dependence that is the distinguishing claim of this hypothesis.

PMID:40139558 SUPPORT In Vitro

"redundant activities of TGFβ isoforms provide implications about the milder TAAD aggressiveness of pathogenic TGFB2 variants"

Offers the model's explanation for why LDS4 is clinically milder than receptor-gene Loeys-Dietz. Marked PARTIAL because it is an inference the authors draw from isoform redundancy in vitro, not a measured clinical comparison.

?

Discussions and Knowledge Gaps

3

By what mechanism does heterozygous loss of function of TGFB2 produce aortic tissue with increased canonical and non-canonical TGF-beta signalling, and is that excess the cause of medial degeneration or a marker of it?

KNOWLEDGE GAP OPEN tgfb2_signaling_direction_paradox

Attached to

pathophysiology#Paradoxical Aortic TGF-beta Signaling Dysregulation

Every measurement in LDS4 that is made in a peripheral cell shows less TGF-beta 2; every measurement made in the diseased aorta shows more TGF-beta signalling. Several non-exclusive explanations are on the table - relief of a canonical negative-feedback loop driving ligand expression and non-canonical overactivation; a shift in isoform usage towards TGF-beta 1; a non-cell-autonomous paracrine effect between smooth muscle populations of different embryonic origin at the transition zones where aneurysms form; and recruitment of angiotensin II or activin signalling. The 2018 mutation update states explicitly that the mechanism remains elusive. This is not an academic point: it determines whether a TGF-beta-directed therapy should augment or suppress signalling, and the observed excess may equally be a repair response to matrix damage rather than its cause.

Proposed experiments

Compartment-matched signalling measurement

lds4_compartment_matched_signalling

Measure TGF-beta 2 ligand, pSMAD2 and pERK1/2 in aortic media, adventitia and dermal fibroblasts from the same TGFB2-variant individuals, to establish whether the direction of the signalling change is tissue-compartment-specific rather than a whole-organism property.

Temporal ordering in the haploinsufficient mouse

lds4_temporal_ordering_mouse

Determine in Tgfb2+/- mice whether the rise in aortic pSmad2/3 and Erk1/2 precedes or follows the first detectable elastic fibre fragmentation, to discriminate a causal excess from a reparative response.

Show evidence (1 reference)

PMID:29392890 SUPPORT Human Clinical

"Although TGFB2 mutations are predicted to result in haploinsufficiency, the exact mechanisms on how loss‐of‐function mutations lead to a paradoxical activation of TGF‐β signaling remain elusive."

An explicit statement from the field's mutation update that this mechanism is unresolved - the definition of the gap recorded here.

Is the hypotonia, gross motor delay and speech delay/intellectual disability reported in patients with 1q41 deletions encompassing TGFB2 attributable to TGFB2 haploinsufficiency itself, or to the neighbouring genes also removed by the deletion?

KNOWLEDGE GAP OPEN tgfb2_deletion_neurodevelopmental_phenotype

Attached to

pathophysiology#TGFB2 Loss-of-Function Variant

Neurodevelopmental abnormalities are not a recognised feature of Loeys-Dietz syndrome, yet seven of nine reported patients with pure 1q41 deletions involving TGFB2 had hypotonia and gross motor delay and three had speech delay and/or intellectual disability. The smallest common deletion contains two genes, RRP15 and TGFB2, so the deletion series cannot on its own assign the phenotype to TGFB2. This matters directly for how an LDS4 diagnosis is counselled: whether a child with a whole-gene deletion carries a neurodevelopmental risk that a child with an intragenic TGFB2 point mutation does not.

Proposed experiments

Intragenic-variant neurodevelopmental cohort comparison

lds4_intragenic_vs_deletion_neurodev

Systematically assess development in a cohort of patients with intragenic TGFB2 loss-of-function variants and compare with the 1q41 whole-gene deletion series; a neurodevelopmental signal restricted to deletion carriers would implicate the contiguous genes rather than TGFB2.

The same attribution problem extends beyond neurodevelopment. A 4.7 Mb 1q41 deletion encompassing TGFB2 has been reported with Loeys-Dietz features together with adult-onset osteoporosis (PMID:28544325) - osteoporosis is not a recognised feature of LDS4 from intragenic variants either, so the deletion series may be accumulating a contiguous-gene phenotype rather than an expanded TGFB2 phenotype. That report is indexed as a Letter with no abstract, so it is recorded here and as a top-level reference rather than as an evidence item; the proposed intragenic-versus-deletion cohort comparison should score skeletal density alongside development.

Show evidence (2 references)

PMID:35426477 SUPPORT Human Clinical

"The smallest deletion common to all patients is a 785 kb locus that contains two genes: RRP15 and TGFB2."

States the contiguous-gene ambiguity that makes the attribution question open.

PMID:35426477 SUPPORT Human Clinical

"Seven of the nine patients present with some degree of hypotonia and gross motor delay, and three of the nine present with speech delay and/or intellectual disability (ID)."

Quantifies the neurodevelopmental findings in the deletion series that prompt the question.

Does cervical spine malformation and/or instability occur in TGFB2-related Loeys-Dietz syndrome, or is it confined to the receptor-related subtypes?

KNOWLEDGE GAP OPEN lds4_cervical_spine_instability_subtype_status

Attached to

pathophysiology#Reduced TGF-beta 2 Ligand Availability

The two sources disagree in scope rather than in fact. GeneReviews lists cervical spine malformation and/or instability among the defining skeletal manifestations of Loeys-Dietz syndrome and recommends orthopaedic follow-up and, where necessary, surgical fixation - but that account is written across SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, TGFBR2 and IPO8 collectively and makes no per-gene assignment. The only TGFB2-specific statement in the literature runs the other way: the 2018 mutation update reports that cervical spine instability has not yet been seen in TGFB2/TGFB3 patients, and uses that absence as one of the features distinguishing the ligand-related from the receptor-related subtypes. Because a spectrum-level list cannot establish a feature in one subtype while the subtype-specific literature records it as unobserved, this manifestation is deliberately NOT curated as an LDS4 phenotype and no surgical-fixation treatment is curated for it; the distinguishing_features block records the negation instead. This is an absence of report rather than a demonstrated absence - LDS4 is rare, the published series are small, and no study has systematically imaged the cervical spine in a TGFB2 cohort - so the question is recorded as open rather than closed. The management consequence is real either way: if the feature does occur at low frequency in TGFB2 carriers it bears on neck positioning and intubation during the prophylactic aortic surgery that defines this disorder's care pathway.

Proposed experiments

Systematic cervical spine imaging in a TGFB2 cohort

lds4_cervical_spine_imaging_cohort

Perform flexion-extension radiography or cross-sectional cervical spine imaging prospectively in a molecularly confirmed TGFB2 cohort, with a TGFBR1/TGFBR2 comparison group ascertained the same way, to establish whether the reported absence in TGFB2 reflects a genuine genotype difference or ascertainment - existing TGFB2 reports are aortic-led and largely did not image the cervical spine.

Curation decision, recorded so the reasoning is not lost: the GeneReviews skeletal-manifestation and orthopaedic-management sentences were mined during review and are preserved above as PARTIAL evidence on this gap rather than being promoted to a phenotype and a treatment block, which would have contradicted the entry's own description and differential_diagnoses. The other seven GeneReviews spectrum-level features curated in this entry (allergy, asthma, eczema, eosinophilic esophagitis, gastritis, inflammatory bowel disease, pregnancy complications) carry no such TGFB2-specific negation and are curated normally.

Show evidence (3 references)

PMID:29392890 SUPPORT Human Clinical

"For example cervical spine instability has not yet been seen in TGFB2/3 mutations patients, and craniosynostosis has only been reported once in a SMAD3 patient."

The TGFB2-specific statement that the feature has not been observed in this subtype - the reason it is not curated as an LDS4 phenotype.

PMID:20301312 SUPPORT INDIRECT Human Clinical

"skeletal manifestations (pectus excavatum or pectus carinatum, scoliosis, joint laxity, arachnodactyly, talipes equinovarus, and cervical spine malformation and/or instability)"

GeneReviews lists the manifestation for Loeys-Dietz syndrome as a whole. Marked INDIRECT because the account spans all seven Loeys-Dietz genes and makes no per-gene assignment, so it does not establish the feature in the TGFB2 subtype.

PMID:20301312 SUPPORT Human Clinical

"Surgical fixation of cervical spine instability may be necessary to prevent spinal cord damage."

The management pathway that would follow if the feature were established in TGFB2 carriers. Retained here rather than as a curated treatment because its indication - the phenotype itself - is not established for this subtype.

⚙

Pathophysiology

7

TGFB2 Loss-of-Function Variant

Heterozygous TGFB2 variants are the genetic trigger of LDS4. The reported allelic spectrum is dominated by predicted loss-of-function classes - nonsense, frameshift, splice-site and whole- or partial-gene deletion - with a minority of missense alleles; deletions at 1q41 encompassing the whole gene produce the same phenotype, which is the strongest human argument that the mechanism is simple haploinsufficiency rather than a dominant-negative protein. A substantial share of the reported variants fall in the latency-associated peptide (LAP) domain or the RKKR furin cleavage motif required to release the mature TGF-beta 2 cytokine from LAP. Where a frameshift escapes nonsense-mediated decay, the mutant transcript is present but the proprotein is degraded, so the net effect is still reduced cellular TGF-beta 2.

TGFB2 hgnc:11768

Downstream

Reduced TGF-beta 2 Ligand Availability Loss of one functional TGFB2 allele halves the cellular supply of mature TGF-beta 2 ligand.

Show evidence (4 references)

PMID:22772368 SUPPORT Human Clinical

"Here, we report heterozygous mutations or deletions in the gene encoding the TGF-β2 ligand for a phenotype within the LDS spectrum"

The defining observation for LDS4: heterozygous TGFB2 mutations and whole-gene deletions produce a Loeys-Dietz-spectrum phenotype.

PMID:22772371 SUPPORT Human Clinical

"the mutations are predicted to cause haploinsufficiency for TGFB2"

States the predicted molecular consequence of the identified alleles.

PMID:22772371 SUPPORT In Vitro

"These data suggest that although the deleted transcript is expressed, the mutant protein is rapidly degraded by an endoplasmic reticulum-associated degradation pathway, resulting in decreased cellular levels of wildtype TGF-β2."

Explains how a frameshift allele that escapes nonsense-mediated decay still yields functional haploinsufficiency - the protein, not the message, is lost.

+ 1 more reference

Reduced TGF-beta 2 Ligand Availability

The proximal biochemical consequence of a TGFB2 loss-of-function allele is reduced cellular TGF-beta 2 proprotein and mature ligand. In smooth muscle cells and dermal fibroblasts from affected family members, TGFB2 transcript levels were comparable to control but TGF-beta 2 proprotein was reduced and no truncated protein was detectable. Crucially, this reduction is measured in peripheral cells and is the opposite of what the diseased aorta shows, which is what sets up the disorder's central paradox.

Compensatory ligand overshoot (canonical model of the TGF-beta paradox) TGFBR3-dependent aortic root smooth muscle differentiation defect

vascular smooth muscle cell CL:0000359 dermal fibroblast CL:0000057

transforming growth factor beta receptor signaling pathway GO:0007179 ↓ DECREASED

Downstream

Paradoxical Aortic TGF-beta Signaling Dysregulation Reduced cellular TGF-beta 2 provokes a compensatory response in the aortic wall that overshoots into excess TGF-beta signalling.

Impaired Aortic Root Smooth Muscle Cell Differentiation TGF-beta 2 is required, via TGFBR3, for differentiation of the second heart field-derived smooth muscle cells that populate the aortic root.

Show evidence (2 references)

PMID:22772371 SUPPORT In Vitro

"immunoblot analysis of the TGF-β2 proprotein in cellular lysates from these cells showed reduced TGF-β2 proprotein levels in the mutant cells compared with the wildtype cells and no evidence of the truncated protein"

Direct measurement of reduced TGF-beta 2 proprotein in patient-derived smooth muscle cells and fibroblasts, with no truncated species - the biochemical definition of haploinsufficiency here.

PMID:22772371 SUPPORT Human Clinical

"the initial pathway driving disease is decreased cellular TGF-β2 levels leading to a secondary increase in TGF-β2 production in the diseased aorta"

States the authors' sequencing of the two directions: cellular loss first, aortic overshoot second. This is the causal ordering this node encodes.

Paradoxical Aortic TGF-beta Signaling Dysregulation

Despite the loss-of-function genetics, aortic wall tissue from TGFB2-variant patients shows the same high-TGF-beta tissue signature as the rest of the Loeys-Dietz spectrum: increased nuclear phosphorylated SMAD2 in medial smooth muscle cells and increased CTGF expression, together with paradoxically increased TGF-beta 2 and TGF-beta 1 ligand expression and protein. In the Tgfb2 heterozygous mouse both the canonical (pSmad2/3) and non-canonical (pErk1/2) arms are activated, so the dysregulation is not confined to the SMAD branch. This node is the conserved hub of the heritable-aortopathy module, reached here from a ligand rather than a receptor lesion.

aortic medial smooth muscle cell CL:0000359

SMAD protein signal transduction GO:0060395 ↑ INCREASED ERK1 and ERK2 cascade GO:0070371 ↑ INCREASED

Animal models

Tgfb2 heterozygous null mouse (Tgfb2+/-) Mouse recapitulates The heterozygous null genotype matches the human haploinsufficiency mechanism exactly, and the aortic tissue reproduces both the canonical and non-canonical signalling increase seen in patient aorta.

Downstream

Aortic Medial Degeneration Sustained excess TGF-beta signalling in the media drives elastic fibre breakdown and proteoglycan accumulation.

Show evidence (4 references)

PMID:22772368 SUPPORT Human Clinical

"show upregulation of TGF-β signaling in aortic tissue from affected individuals"

Documents increased TGF-beta signalling in the aortic tissue of TGFB2 patients.

PMID:29392890 SUPPORT Human Clinical

"increased pSMAD2 and CTGF expression was observed in the aortic media of patients with either loss‐of‐function TGFB2 or TGFB3 mutations, further confirming the paradoxical observation of increased TGF‐β signaling in vivo"

Localises the increased canonical signalling and its transcriptional output (CTGF) specifically to the aortic media of TGFB2 patients.

PMID:27782106 SUPPORT Human Clinical

"There was striking upregulation of TGFB1 and TGFB2 expression on immunofluorescent staining, and western blotting of the aortic tissue from the index case"

Independent confirmation in a missense-allele pedigree that both TGF-beta 1 and TGF-beta 2 are up-regulated in the LDS4 aorta.

+ 1 more reference

Impaired Aortic Root Smooth Muscle Cell Differentiation

A developmental arm that helps explain why the aneurysm in LDS4 is concentrated at the aortic root. In human iPSC-derived smooth muscle cells, TGFB2 signals distinctively through TGFBR3 (betaglycan) rather than only the canonical type I/II receptors, and both TGFB2 and TGFBR3 are enriched in the tunica media of the aortic root specifically. TGFB2 haploinsufficiency and TGFB2 neutralisation impair differentiation of second heart field-derived smooth muscle cells - the lineage that populates the root - and a missense TGFB2 variant produced measurable mechanical defects in engineered smooth muscle tissue rings that were rescued by adding back TGFB2. This arm is grounded entirely in an in vitro human system; it complements rather than replaces the paradoxical-signalling arm.

second heart field-derived smooth muscle cell CL:0000359

smooth muscle cell differentiation GO:0051145 ↓ DECREASED

Experimental models

TGFB2-KO/+ human iPSC-derived smooth muscle cells and 3D tissue rings IPSC DERIVED MODEL Reproduces impaired differentiation of second heart field-derived smooth muscle cells under the exact human genotype (TGFB2 haploinsufficiency), with epistasis showing the effect runs through TGFBR3.

Downstream

Aortic Medial Degeneration A structurally deficient root media is more vulnerable to the degenerative process.

Show evidence (2 references)

PMID:40139558 SUPPORT In Vitro

"TGFB2 haploinsufficiency (TGFB2KO/+) and TGFB2 neutralization impaired the differentiation of second heart field-derived SMCs."

Direct demonstration that TGFB2 haploinsufficiency - the LDS4 genotype - impairs differentiation of the smooth muscle lineage that builds the aortic root.

PMID:40139558 SUPPORT In Vitro

"Molecular evaluation of different thoracic aorta regions suggested TGFB2 and TGFBR3 enrichment in the aortic root tunica media."

Provides the regional explanation for root-predominant disease: the TGFB2-TGFBR3 axis is enriched exactly where the aneurysm forms.

Aortic Medial Degeneration

The histological lesion of LDS4 is the medial degeneration common to the heritable aortopathies: fragmentation and loss of elastic fibres in the tunica media with accumulation of proteoglycans, described in both of the 2012 defining cohorts and independently as cystic medial necrosis in a dissected LDS4 aorta. The result is a media that has lost its recoil and tensile competence.

extracellular matrix organization GO:0030198 ⚠ ABNORMAL elastic fiber assembly GO:0048251 ↓ DECREASED

Downstream

Progressive Aortic Root Dilation A weakened media dilates under normal haemodynamic load.

Show evidence (2 references)

PMID:22772371 SUPPORT Human Clinical

"The aortic pathology typical for thoracic aortic disease was found, which is characterized by fragmentation and loss of elastin fibers and accumulation of proteoglycans in the tunica media"

Describes the medial lesion directly in aortic tissue from two TGFB2 patients.

PMID:27782106 SUPPORT Human Clinical

"Histologic examination showed fragmentation and disruption of the aortic elastic fibers and cystic medial necrosis"

Independent histological confirmation in the resected aorta of a TGFB2-variant patient who had sustained a type A dissection.

Progressive Aortic Root Dilation

Aortic root dilation at the sinuses of Valsalva is the principal cardiovascular manifestation. In LDS4 it characteristically appears later than in the receptor-related subtypes - typically in the fourth decade - and progresses more slowly, which is the clinical basis for calling LDS4 the mild end of the Loeys-Dietz spectrum. Aneurysm and ectasia elsewhere in the arterial tree (iliac, carotid, vertebral, cerebral, pulmonary) and arterial tortuosity also occur, so surveillance cannot be limited to echocardiography of the root.

Animal models

Tgfb2 heterozygous null mouse (Tgfb2+/-) Mouse recapitulates Tgfb2+/- mice develop dilation of the aortic annulus and aortic root, matching the anatomical distribution of human LDS4 aneurysm.

Downstream

Aortic Dissection and Rupture A dilated, degenerate root can dissect or rupture, though less frequently in LDS4 than in the receptor-related subtypes.

Show evidence (2 references)

PMID:25163805 SUPPORT Human Clinical

"LDS4 represents the mildest end of the LDS spectrum, since aneurysms are usually observed in fourth decade and the progression of the disease is slower than in the other forms."

States the characteristic later onset and slower progression that distinguish the LDS4 aortic phenotype.

PMID:29392890 SUPPORT Human Clinical

"The aortic phenotype in patients with SMAD3 mutations is very similar to TGFBR1/2 patients, whereas TGFB2 and TGFB3 cardiovascular features tend to be milder, although severe aortic presentation at young age has also been observed."

Places the TGFB2 aortic phenotype at the milder end of the spectrum while explicitly preserving the exception - severe young-onset disease occurs.

Aortic Dissection and Rupture

The lethal endpoint. Type A dissection extending the full length of the aorta, dissection of abdominal aortic aneurysm, and sudden death have all been reported in TGFB2 pedigrees, and it was the occurrence of dissection and death across multiple generations that led to gene identification. Relative to LDS1/LDS2, dissection in LDS4 is less frequent, but it is not absent - families ascertained through sudden death are on record, and descending aortic dissection can occur while root dilation is still relatively mild.

Show evidence (3 references)

PMID:27782106 SUPPORT Human Clinical

"A CT scan with contrast showed a Stanford type-A dissection with an intimal flap extending the full length of the aorta from the aortic valve into both iliac arteries"

Documents an extensive type A dissection as the presenting event in a TGFB2-variant patient.

PMID:41170304 SUPPORT Human Clinical

"responsible of LDS4 in a family with sudden death and vascular lesions"

Records sudden death within a TGFB2 pedigree, the reason the milder-end characterisation must not be read as benign.

PMID:38919319 SUPPORT Human Clinical

"due care should be paid to the fact that descending aortic dissection can occur even if dilatation at the root is relatively mild"

The clinically decisive qualifier on the milder-phenotype framing: dissection risk in the non-root aorta is not indexed to root diameter.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

27

Blood 1

Bruising Susceptibility HP:0000978

Show evidence (1 reference)

PMID:34680857 SUPPORT Human Clinical

"The second group, shared only with LDSs, includes arterial tortuosity, a bicuspid aortic valve, hypertelorism, bifid uvula, thin skin with easy bruising, and club feet."

Records thin skin with easy bruising among the Loeys-Dietz-specific features in the original TGFB2 families.

Cardiovascular 5

Aortic Root Aneurysm VERY_FREQUENT HP:0002616

Course: PROGRESSIVE

Show evidence (2 references)

PMID:29392890 SUPPORT Human Clinical

"The most important clinical finding in LDS patients is dilatation of the aortic root at the level of the sinuses of Valsalva, a feature that nearly all LDS patients will develop ultimately."

Establishes aortic root dilation as the near-universal cardiovascular finding across the Loeys-Dietz spectrum, and supports the VERY_FREQUENT band ("nearly all").

PMID:34680857 SUPPORT Human Clinical

"In LDS4 (MIM#614816), unlike MFS, aortic aneurysm involves mainly, but not exclusively, the sinus of Valsalva at a later onset than the age of thirtyfive"

Specifies the LDS4 pattern: sinus of Valsalva predominant, onset after the mid-thirties.

Aortic Dissection OCCASIONAL HP:0002647

Show evidence (2 references)

PMID:27782106 SUPPORT Human Clinical

"A CT scan with contrast showed a Stanford type-A dissection with an intimal flap extending the full length of the aorta from the aortic valve into both iliac arteries"

Documents type A dissection in a TGFB2-variant patient.

PMID:34680857 SUPPORT Human Clinical

"The aortic ectasia is relatively mild and has a lower incidence of dissection, compared to the other LDS types"

Supports the OCCASIONAL rather than FREQUENT band: dissection incidence in LDS4 is explicitly lower than in the other Loeys-Dietz subtypes.

Arterial Tortuosity FREQUENT HP:0005116

Show evidence (2 references)

PMID:29392890 SUPPORT Human Clinical

"3D reconstruction of images from the head to pelvis is needed to identify arterial tortuosity, present in most individuals with a TGFBR1/2, TGFB2, or SMAD3 mutation"

States that arterial tortuosity is present in most individuals carrying a TGFB2 mutation, supporting the FREQUENT band, and names the imaging required to detect it.

PMID:25163805 SUPPORT Human Clinical

"Magnetic resonance angiography revealed tortuosity and ectasia of carotid, vertebral, cerebral, and segmental pulmonary arteries."

Enumerates the arterial territories involved in a TGFB2 proband who never had an aneurysm or dissection - tortuosity was the vascular finding.

Mitral Valve Prolapse HP:0001634

Show evidence (3 references)

PMID:25163805 SUPPORT Human Clinical

"dural ectasia, and mitral valve prolapse"

Records mitral valve prolapse among the proband's findings.

PMID:25163805 SUPPORT Human Clinical

"described other 6 sporadic LDS4 patients with TGFB2 mutations, pointing out a high rate of mitral valve disease, suggesting that this might be a signature feature of the disorder that may direct molecular analysis"

Summarises the Renard et al. TGFB2 series (PMID:23102774), which is indexed in PubMed as a Letter with no abstract and therefore cannot itself supply a verifiable snippet. This sentence carries the substantive claim - a high rate of mitral valve disease proposed as a signature feature of LDS4 - rather than the five-word fragment it replaces as primary support.

PMID:41170304 SUPPORT Human Clinical

"LDS subtypes induce cardiovascular complications, including arterial tortuosity, aortic aneurysms and dissections, mitral valve prolapse, and arthritis."

Lists mitral valve prolapse among the cardiovascular complications of the Loeys-Dietz subtypes, LDS4 included.

Bicuspid Aortic Valve HP:0001647

Show evidence (1 reference)

PMID:34680857 SUPPORT Human Clinical

"The second group, shared only with LDSs, includes arterial tortuosity, a bicuspid aortic valve, hypertelorism, bifid uvula, thin skin with easy bruising, and club feet."

Places bicuspid aortic valve among the features observed across the eight original TGFB2 families and shared with the Loeys-Dietz subtypes rather than with Marfan syndrome.

Digestive 1

Recurrent Hernia Inguinal hernia HP:0000023

Temporal: RECURRENT

Show evidence (2 references)

PMID:25163805 SUPPORT Human Clinical

"chronic pain, scoliosis, multiple relapsing hernias, dural ectasia"

Documents multiple relapsing hernias in a molecularly confirmed LDS4 proband.

PMID:29392890 SUPPORT Human Clinical

"Additionally, osteoarthritis and hernia (mostly inguinal) have been frequently observed in all LDS types"

Establishes hernia, usually inguinal, as a frequent finding across the Loeys-Dietz types including TGFB2.

Eye 1

Hypertelorism HP:0000316

Show evidence (1 reference)

PMID:34680857 SUPPORT Human Clinical

"LDS4 is characterised by the presence of hypertelorism, cleft palate and/or bifid uvula, with possible ectasia or aneurysms in other arteries."

Names hypertelorism as a characterising craniofacial feature of LDS4 specifically.

Head and Neck 3

Bifid Uvula HP:0000193

Show evidence (1 reference)

PMID:34680857 SUPPORT Human Clinical

"The second group, shared only with LDSs, includes arterial tortuosity, a bicuspid aortic valve, hypertelorism, bifid uvula, thin skin with easy bruising, and club feet."

Assigns bifid uvula to the group of features shared only with Loeys-Dietz, as observed across the eight original TGFB2 families.

Cleft Palate VERY_RARE HP:0000175

Show evidence (1 reference)

PMID:29392890 SUPPORT Human Clinical

"For the first time, we report on cleft palate in patients with TGFB2 mutations."

Records the first observation of cleft palate in TGFB2 patients. The "first time" framing after a large multicentre series is why the frequency is banded VERY_RARE rather than higher.

High Palate HP:0000218

Show evidence (1 reference)

PMID:25163805 SUPPORT Human Clinical

"showed high palate, hypoplasic uvula, easy bruising, joint hypermobility"

Documents high palate in a molecularly confirmed LDS4 proband.

Immune 1

Eczema Eczematoid dermatitis HP:0000964

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"allergic/inflammatory disease including asthma, eczema, and reactions to food or environmental allergens"

Names eczema among the allergic manifestations of Loeys-Dietz syndrome.

Integument 1

Striae Distensae HP:0001065

Show evidence (1 reference)

PMID:34680857 SUPPORT Human Clinical

"the first group common to MFS and LDS including aortic aneurysm, pectus deformity, scoliosis, arachnodactyly, and skin striae"

Lists skin striae among the Marfan-overlapping features in the original TGFB2 families.

Limbs 2

Arachnodactyly HP:0001166

Show evidence (1 reference)

PMID:34680857 SUPPORT Human Clinical

"the first group common to MFS and LDS including aortic aneurysm, pectus deformity, scoliosis, arachnodactyly, and skin striae"

Lists arachnodactyly among the Marfan-overlapping features in the original TGFB2 families.

Talipes Equinovarus HP:0001762

Show evidence (1 reference)

PMID:34680857 SUPPORT Human Clinical

"The second group, shared only with LDSs, includes arterial tortuosity, a bicuspid aortic valve, hypertelorism, bifid uvula, thin skin with easy bruising, and club feet."

Records clubfoot among the Loeys-Dietz-specific features seen in the original TGFB2 families.

Musculoskeletal 4

Scoliosis HP:0002650

Show evidence (2 references)

PMID:34680857 SUPPORT Human Clinical

"the first group common to MFS and LDS including aortic aneurysm, pectus deformity, scoliosis, arachnodactyly, and skin striae"

Places scoliosis among the features observed across the eight original TGFB2 families.

PMID:25163805 SUPPORT Human Clinical

"joint hypermobility, chronic pain, scoliosis, multiple relapsing hernias"

Independent observation of scoliosis in a molecularly confirmed LDS4 proband.

Joint Hypermobility FREQUENT HP:0001382

Show evidence (2 references)

PMID:25163805 SUPPORT Human Clinical

"easy bruising, joint hypermobility, chronic pain, scoliosis"

Documents joint hypermobility in a molecularly confirmed LDS4 proband.

PMID:25163805 SUPPORT Human Clinical

"loss-of-function mutations in TGFB2 gene do not always lead to aggressive vascular phenotypes and that articular and skeletal signs are prevalent"

Supports the FREQUENT band for articular findings in LDS4 and the claim that they may dominate the presentation.

Osteoarthritis HP:0002758

Show evidence (1 reference)

PMID:29392890 SUPPORT Human Clinical

"Additionally, osteoarthritis and hernia (mostly inguinal) have been frequently observed in all LDS types"

Records osteoarthritis as a frequent finding across the Loeys-Dietz types including TGFB2-related disease.

Hypotonia and Gross Motor Delay HP:0001252

Show evidence (2 references)

PMID:35426477 SUPPORT Human Clinical

"Seven of the nine patients present with some degree of hypotonia and gross motor delay, and three of the nine present with speech delay and/or intellectual disability (ID)."

Quantifies the finding in the 1q41 deletion series. Marked PARTIAL because the deletion encompasses a second gene, so the evidence supports the association with the deletion but not with TGFB2 haploinsufficiency specifically.

PMID:35426477 SUPPORT Human Clinical

"Neurodevelopmental abnormalities are uncommon in LDS."

Establishes the baseline expectation this finding departs from, which is why it is curated with an explicit attribution caveat.

Other 8

Pectus Deformity Abnormal sternum morphology HP:0000766

Show evidence (1 reference)

PMID:34680857 SUPPORT Human Clinical

"the first group common to MFS and LDS including aortic aneurysm, pectus deformity, scoliosis, arachnodactyly, and skin striae"

Lists pectus deformity among the features observed in the original TGFB2 families.

Dural Ectasia HP:0100775

Show evidence (1 reference)

PMID:25163805 SUPPORT Human Clinical

"multiple relapsing hernias, dural ectasia, and mitral valve prolapse"

Documents dural ectasia in a molecularly confirmed LDS4 proband.

Allergic and Inflammatory Predisposition Allergy HP:0012393

Show evidence (2 references)

PMID:20301312 SUPPORT Human Clinical

"Individuals with LDS can show a strong predisposition for allergic/inflammatory disease including asthma, eczema, and reactions to food or environmental allergens."

GeneReviews states the allergic/inflammatory predisposition across Loeys-Dietz syndrome and enumerates its manifestations.

clinicaltrials:NCT05472519 SUPPORT Other

"immuno-allergic manifestations (asthma, eczema, food allergy, eosinophilic esophagitis, chronic inflammatory bowel disease)"

An independent enumeration of the same immuno-allergic manifestation set, from the registration record of a study designed around it. Marked OTHER because a trial registration is a study description, not study evidence.

Asthma HP:0002099

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"strong predisposition for allergic/inflammatory disease including asthma"

Names asthma among the allergic manifestations of Loeys-Dietz syndrome.

Eosinophilic Esophagitis Eosinophilic infiltration of the esophagus HP:0410151

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"There is also an increased incidence of gastrointestinal inflammation including eosinophilic esophagitis and gastritis or inflammatory bowel disease."

States the increased incidence of gastrointestinal inflammation and names eosinophilic esophagitis as one of its forms.

Gastritis HP:0005263

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"increased incidence of gastrointestinal inflammation including eosinophilic esophagitis and gastritis"

Names gastritis among the gastrointestinal inflammatory manifestations.

Inflammatory Bowel Disease Inflammation of the large intestine HP:0002037

Show evidence (2 references)

PMID:20301312 SUPPORT Human Clinical

"gastrointestinal inflammation including eosinophilic esophagitis and gastritis or inflammatory bowel disease"

Names inflammatory bowel disease among the gastrointestinal inflammatory manifestations.

clinicaltrials:NCT05472519 SUPPORT Other

"eosinophilic esophagitis, chronic inflammatory bowel disease"

Independently lists chronic inflammatory bowel disease among the immuno-allergic manifestations of Loeys-Dietz syndrome.

🧬

Genetic Associations

1

TGFB2 (Causative)

Gene: TGFB2 hgnc:11768 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (6 references)

PMID:22772368 SUPPORT Human Clinical

"Here, we report heterozygous mutations or deletions in the gene encoding the TGF-β2 ligand for a phenotype within the LDS spectrum"

The primary gene-disease assertion for LDS4.

PMID:29392890 SUPPORT Human Clinical

"We report 7, 67, 30, and 15 different variants for SMAD2, SMAD3, TGFB2, and TGFB3, respectively"

Gives the catalogued TGFB2 variant count as of the field's mutation update.

PMID:39737004 SUPPORT In Vitro

"Molecular validation of the splicing products suggests that the TGFB2 variants tested impact splicing by reducing efficiency of the canonical acceptor in favor of an alternate acceptor within the exon."

Functional characterisation of a near-splice-site intronic TGFB2 variant class that panel sequencing would classify as uncertain.

+ 3 more references

💊

Medical Actions

9

Angiotensin Receptor Blocker Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: losartan CHEBI:6541 angiotensin II receptor antagonist NCIT:C66930

Angiotensin receptor blockers are used across the Loeys-Dietz spectrum to reduce haemodynamic stress on the aortic wall, and losartan additionally antagonises TGF-beta signalling - the pathway implicated in the disorder. Note that the direction of the underlying signalling defect in LDS4 is unresolved (see the tgfb2_signaling_direction_paradox discussion), so the rationale for TGF-beta-directed therapy here rests on the observed aortic high-TGF-beta tissue signature rather than on a settled model, and there are no TGFB2-specific efficacy trials. Critically, angiotensin receptor blockers are contraindicated in pregnancy, so the first-line medical therapy of LDS4 must be reviewed and switched before conception - in a disorder whose pregnancy risk is itself elevated and whose diagnosis is often made only after childbearing, this is a routine rather than exceptional decision.

Mechanism Target:

INHIBITS Paradoxical Aortic TGF-beta Signaling Dysregulation — Losartan reduces haemodynamic wall stress and has TGF-beta-antagonist activity, targeting the dysregulated aortic signalling node.

Show evidence (2 references)

PMID:20301312 SUPPORT Human Clinical

"angiotensin receptor blockers, beta-adrenergic receptor blockers, or other medications are used to reduce hemodynamic stress"

GeneReviews states the medical management of the cardiovascular features of Loeys-Dietz syndrome, of which LDS4 is a subtype.

PMID:30725712 SUPPORT Human Clinical

"These medications are contraindicated during pregnancy and require caution in patients with bilateral renal artery stenosis."

"These medications" are angiotensin II receptor blockers, the class named throughout this source. Marked PARTIAL because it is a class-level safety statement rather than Loeys-Dietz-specific evidence; it constrains when the treatment may be used, not whether it works.

Beta-Blocker Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: beta-adrenergic antagonist NCIT:C29576

Beta-adrenergic receptor blockade to reduce the rate of rise of aortic pressure and thereby haemodynamic stress on a dilating aortic root.

Mechanism Target:

INHIBITS Progressive Aortic Root Dilation — Reducing haemodynamic stress slows the rate of aortic root dilation.

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"angiotensin receptor blockers, beta-adrenergic receptor blockers, or other medications are used to reduce hemodynamic stress"

GeneReviews names beta-adrenergic receptor blockers as part of the medical management of Loeys-Dietz cardiovascular disease.

Prophylactic Aortic Root Replacement

Action: Surgical Procedure NCIT:C15329

Elective surgical replacement of the aortic root before dissection occurs. Across the Loeys-Dietz spectrum the threshold for intervention is lower than in Marfan syndrome because dissection can occur at smaller diameters, and the vascular disease is not confined to the root. Because dissection risk in TGFB2 disease is lower than in TGFBR1/TGFBR2 disease, the most aggressive Loeys-Dietz thresholds should be individualised rather than applied automatically in LDS4.

Mechanism Target:

INHIBITS Aortic Dissection and Rupture — Replacing the dilated root removes the segment at risk of dissection.

Show evidence (2 references)

PMID:20301312 SUPPORT Human Clinical

"aortic dissection can occur at smaller aortic diameters and at younger ages than observed in Marfan syndrome; vascular disease is not limited to the aortic root; angiotensin receptor blockers, beta-adrenergic receptor blockers, or other medications are used to reduce hemodynamic stress; and..."

States the rationale for early and aggressive surgical intervention and the lower diameter threshold that applies across Loeys-Dietz syndrome.

PMID:38919319 SUPPORT Human Clinical

"the risk of dissection is not so high when the causative gene is any of the latter three genes"

Supports individualising rather than automatically applying the most aggressive Loeys-Dietz surgical threshold in TGFB2 disease. Marked PARTIAL because the review states the risk difference, not a TGFB2-specific diameter threshold.

Avoidance of Cardiovascular Stressors

Action: Supportive Care NCIT:C15747

Agents and circumstances to avoid across the Loeys-Dietz spectrum, per GeneReviews: contact and competitive sports, isometric exercise, and agents that stimulate the cardiovascular system including routine decongestants and triptans for migraine.

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"Contact sports, competitive sports, and isometric exercise; agents that stimulate the cardiovascular system including routine use of decongestants or triptan medications for the management of migraine headache"

The GeneReviews "Agents/circumstances to avoid" list for Loeys-Dietz syndrome.

Genetic Counseling and Cascade Testing

Action: Genetic Counseling NCIT:C15240

Cascade molecular testing of at-risk relatives is disproportionately important in LDS4 because non-penetrance is comparatively common in TGFB2 families: clinical examination and echocardiography alone will miss carriers who have not yet developed - or never develop - aortic disease but who can transmit the variant. Copy-number analysis must be included, since whole-gene deletions are an established LDS4 mechanism that sequencing alone misses.

Show evidence (2 references)

PMID:20301312 SUPPORT Human Clinical

"Clarify the genetic status of at-risk relatives of any age either by molecular genetic testing"

States the GeneReviews recommendation for evaluation of at-risk relatives.

PMID:41170304 SUPPORT Human Clinical

"We emphasize the relevance of genetic counseling and molecular analysis to identify genetic diseases subtending sudden deaths"

Frames genetic counselling and molecular testing as the intervention that identifies at-risk relatives in families ascertained through sudden death.

Subacute Bacterial Endocarditis Prophylaxis

Action: Antibiotic Prophylaxis NCIT:C51993

Antibiotic prophylaxis before dental work or other procedures expected to cause bacteraemia. Relevant in LDS4 because of the valve disease curated here - mitral valve prolapse with regurgitation, bicuspid aortic valve - and because prosthetic material is present in anyone who has undergone prophylactic aortic root replacement. GeneReviews frames this as a consideration rather than a blanket recommendation.

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"Consider subacute bacterial endocarditis prophylaxis in those undergoing dental work or other procedures expected to contaminate the bloodstream with bacteria."

GeneReviews states the prophylaxis recommendation and its trigger procedures for Loeys-Dietz syndrome.

Hernia Repair with Supporting Mesh

Action: Herniorrhaphy NCIT:C168249

Surgical hernia repair reinforced with a supporting mesh. The mesh is not a surgical preference here but a response to the disease mechanism: the same connective-tissue matrix defect that produced the hernia also compromises the repair, so recurrence is expected without reinforcement. This pairs directly with the recurrent hernia phenotype curated above.

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"Hernias tend to recur after surgical intervention; a supporting mesh can be used during surgical repair to minimize recurrence risk."

GeneReviews states both the recurrence problem and the mesh-reinforced repair that addresses it.

Pregnancy Risk Counselling and Intensified Peripartum Aortic Imaging

Action: Supportive Care NCIT:C15747

Preconception counselling on aortic and uterine rupture risk, review and substitution of angiotensin receptor blocker therapy before conception, and increased frequency of aortic imaging both during pregnancy and in the weeks after delivery. The postpartum arm matters as much as the antenatal one: reported Loeys-Dietz peripartum catastrophes cluster in late pregnancy and the puerperium, and in a recent cohort the vascular events that did occur around pregnancy were postpartum. No LDS4-specific pregnancy outcome rate exists, so this is spectrum-level management applied to a subtype whose own risk is uncharacterised.

Show evidence (3 references)

PMID:20301312 SUPPORT Human Clinical

"Increased frequency of aortic imaging is recommended, both during pregnancy and in the weeks following delivery."

GeneReviews states the peripartum imaging intensification recommended for Loeys-Dietz syndrome.

PMID:20301312 SUPPORT Human Clinical

"Pregnancy and the postpartum period can be dangerous for women with LDS because of increased risk of aortic dissection/rupture and uterine rupture."

States the risk that the counselling and intensified imaging are directed at.

PMID:30725712 SUPPORT Human Clinical

"These medications are contraindicated during pregnancy"

Supports the medication-review component: the angiotensin receptor blocker that is first-line therapy outside pregnancy cannot be continued through one. Marked PARTIAL as a class-level safety statement, not Loeys-Dietz-specific evidence.

Allergy and Gastrointestinal Inflammation Management

Action: Supportive Care NCIT:C15747

Standard treatment of allergic and gastrointestinal inflammatory complications, with referral to allergy/immunology in severe disease. Two LDS-specific caveats make this more than generic atopy care: the agents-to-avoid list for the aorta includes routine decongestants, which constrains symptomatic management, and the immuno-allergic phenotype is itself an active research question rather than settled biology. No disease-modifying therapy directed at the allergic arm exists.

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"Standard treatment for allergic complications with consideration of referral to an allergy/immunology specialist in those with severe disease."

GeneReviews states the management approach to the allergic manifestations of Loeys-Dietz syndrome.

🔬

Diagnosis

2

Molecular confirmation of a pathogenic TGFB2 variant

Sequence analysis of TGFB2, in practice through a multigene heritable thoracic aortic disease or connective-tissue panel that also covers TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB3 and FBN1, identifies a heterozygous pathogenic or likely pathogenic TGFB2 variant. Deletion/duplication analysis is not optional in this subtype: whole-gene and contiguous 1q41 deletions are an established LDS4 mechanism that sequencing alone misses, and at least one reported patient carried a working diagnosis of Marfan syndrome until array CGH found the deletion. Testing rather than clinical criteria is frequently what establishes the diagnosis, because the cardiovascular phenotype is milder and later in onset than in TGFBR1/TGFBR2 disease and non-penetrance is comparatively common. A variant of uncertain significance alone does not establish the diagnosis; near-splice-site and deep-intronic alleles are a recognised source of such results and may need RNA-level characterisation.

genetic testing NCIT:C15709

Results: A heterozygous pathogenic or likely pathogenic TGFB2 sequence variant, or a deletion encompassing TGFB2, in a compatible clinical or family context establishes LDS4.

Show evidence (3 references)

PMID:20301312 SUPPORT Human Clinical

"by the identification of a heterozygous pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2 or biallelic pathogenic variants in IPO8 in a proband with aortic root enlargement, type A dissection, other characteristic clinical features of LDS, or a family history of an established..."

GeneReviews states the molecular diagnostic criterion and names TGFB2 among the causal genes.

PMID:34680857 SUPPORT Human Clinical

"Next Generation Sequencing (NGS) analysis, followed by Array-CGH, allowed the detection of a novel chromosomal deletion including the entire TGFB2 gene, confirming not only the clinical suspicion of LDS4"

A worked case in which panel sequencing alone was insufficient and copy number analysis made the diagnosis - the direct support for requiring deletion/duplication coverage in the LDS4 testing strategy.

PMID:39737004 SUPPORT In Vitro

"Molecular validation of the splicing products suggests that the TGFB2 variants tested impact splicing by reducing efficiency of the canonical acceptor in favor of an alternate acceptor within the exon."

Shows the RNA-level work that reclassifies a near-splice-site TGFB2 variant of uncertain significance, the residual-uncertainty branch of this testing pathway.

Baseline and serial whole-arterial-tree imaging

Echocardiography measures the aortic root and ascending aorta at least annually, while MR or CT angiography from head to pelvis at least every other year identifies extra-aortic aneurysms, dissections and arterial tortuosity that echocardiography cannot see. This is not optional adjunct care in LDS4: the disorder's arterial tortuosity and non-root aneurysms are invisible to echocardiography, descending aortic dissection can occur while root dilation is still mild, and in at least one reported case an extra-aortic finding on angiography is what corrected the diagnosis. Imaging frequency is increased for genotype, family history, absolute vessel size or growth rate, and during pregnancy and the postpartum weeks.

Diagnostic Imaging Testing NCIT:C16502

Results: Aortic root and ascending aortic dimensions plus the presence, location and growth rate of aneurysm, dissection or tortuosity anywhere in the arterial tree, which together establish vascular extent and set surveillance interval and prophylactic repair timing.

Modelled in `diagnosis:` rather than `treatments:` deliberately, following the sibling LDS3 entry (Aneurysm-Osteoarthritis_Syndrome): echocardiography and MR/CT angiography are diagnostic procedures used for surveillance, not a device therapy, and nothing about them acts on a pathophysiology node.

Show evidence (3 references)

PMID:20301312 SUPPORT Human Clinical

"Echocardiography to monitor the status of the aortic root and ascending aorta (at least annually) and magnetic resonance angiography or computerized tomography angiography to assess the entire arterial tree (at least every other year)"

States the surveillance imaging schedule recommended for Loeys-Dietz syndrome.

PMID:29392890 SUPPORT Human Clinical

"This is essential because aneurysms distant from the aortic root can be easily overlooked using echocardiography."

States why whole-arterial-tree imaging rather than echocardiography alone is required in TGFB2-related disease.

PMID:38919319 SUPPORT Human Clinical

"careful monitoring is needed for lesions in the branching arteries as well as in the aorta"

Extends the imaging requirement explicitly to the branch arteries, not the aorta alone.

📈

Progression

3

Childhood and adolescence

Age: Birth to second decade

Craniofacial (hypertelorism, bifid uvula, high palate), skeletal (scoliosis, pectus, arachnodactyly, clubfoot) and articular findings may be present from early life, and hernias often present in childhood. Aortic disease is typically not yet manifest, so a child carrying a familial TGFB2 variant may be clinically normal on echocardiography.

Show evidence (1 reference)

PMID:25163805 SUPPORT Human Clinical

"Her 39- and 34-year-old daughters presented with a variable degree of musculoskeletal involvement."

Documents musculoskeletal involvement as the manifestation in younger TGFB2 variant carriers who had not developed vascular disease. Marked PARTIAL because the daughters were adults, so this supports the musculoskeletal-first pattern rather than a specifically childhood onset.

Adulthood - aortic phase

Age: Fourth decade onwards

Aortic root dilation characteristically becomes apparent in the fourth decade and progresses more slowly than in TGFBR1/TGFBR2-related disease. This is the window in which surveillance imaging changes management, and it is also why a normal echocardiogram in a young carrier gives no reassurance about later risk.

Show evidence (1 reference)

PMID:25163805 SUPPORT Human Clinical

"aneurysms are usually observed in fourth decade and the progression of the disease is slower than in the other forms"

States the characteristic timing and tempo of the aortic phase in LDS4.

Complication phase

Age: Variable, typically after the fourth decade

Dissection, rupture and sudden death are the terminal events. They are less frequent than in the receptor-related subtypes but do occur, sometimes as the presenting event in a previously undiagnosed family.

Show evidence (1 reference)

PMID:41170304 SUPPORT Human Clinical

"responsible of LDS4 in a family with sudden death and vascular lesions"

Records sudden death as an outcome in a TGFB2 pedigree.

📊

Prevalence

1

Worldwide

Cases In Literature Unknown

No population prevalence has been established for LDS4 specifically. The 2018 mutation update catalogued 30 distinct TGFB2 variants; the original screen found TGFB2 mutations in only 2 of 276 familial thoracic aortic disease probands. Loeys-Dietz syndrome as a whole has been quoted at roughly 1 in 100,000, of which LDS4 is one of six genetic subtypes and not the commonest. Because non-penetrance is comparatively common in TGFB2 families, ascertained case counts almost certainly understate the number of variant carriers.

Show evidence (2 references)

PMID:22772371 SUPPORT Human Clinical

"Therefore, TGFB2 mutations were identified in 2 out of 276 probands with familial thoracic aortic disease."

The only systematic denominator available for TGFB2 among familial thoracic aortic disease probands.

PMID:39737004 SUPPORT Human Clinical

"Loeys-Dietz syndrome (LDS) is a rare connective tissue disorder with a prevalence of 1 in 100,000 individuals"

Gives the prevalence of Loeys-Dietz syndrome as a whole. Marked PARTIAL because it is not specific to the TGFB2 subtype, which is one of six and not the commonest.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Loeys-Dietz Syndrome 4:

Marfan syndrome MONDO:0007947

Overlapping Features LDS4 is the Loeys-Dietz subtype most easily mistaken for Marfan syndrome: both feature aortic root aneurysm at the sinuses of Valsalva, pectus deformity, scoliosis, arachnodactyly and striae, and the LDS4 aortic phenotype is comparatively mild and late-onset. Patients have carried a clinical Marfan diagnosis for years before a TGFB2 lesion was found.

Distinguishing Features

Marfan syndrome is caused by FBN1 variants; LDS4 by TGFB2 variants or whole-gene deletion, so molecular testing - including copy-number analysis, since whole-gene deletions are a recognised LDS4 mechanism and are missed by sequencing alone - is the definitive discriminator.
Ectopia lentis is characteristic of Marfan syndrome and was not observed in the original TGFB2 families.
Hypertelorism, bifid uvula and cleft palate point to the Loeys-Dietz spectrum rather than Marfan syndrome.
Widespread arterial tortuosity and aneurysm beyond the aortic root favour LDS4; in one reported case it was the appearance of iliac artery ectasia and tortuosity at age 38 that prompted revision of a Marfan diagnosis.

Show evidence (2 references)

PMID:34680857 SUPPORT Human Clinical

"At the age of 38, the appearance of ectasia of the left common iliac artery and tortuosity of the iliac arteries suggested the presence of LDS4."

Documents the clinical feature that redirected a long-standing Marfan diagnosis towards LDS4, and the case in which array-CGH found a whole-gene TGFB2 deletion.

PMID:34680857 SUPPORT Human Clinical

"MFS displays ectopia lentis as a distinguishing, characterising feature, and thoracic aortic ectasia, aneurysm, dissection, and systemic features as manifestations overlapping with LDS4."

States which features separate and which overlap between the two disorders.

Loeys-Dietz syndrome (other genetic subtypes) MONDO:0018954

Overlapping Features The TGFBR1 (LDS1), TGFBR2 (LDS2), SMAD3 (LDS3), TGFB3 (LDS5), SMAD2 (LDS6) and IPO8 subtypes share hypertelorism, bifid uvula/cleft palate, skeletal features, arterial tortuosity and aortic aneurysm with LDS4, and are distinguished by the causal gene together with severity and a few discriminating features.

Distinguishing Features

The LDS1/LDS2 cardiovascular phenotype is more aggressive, with dissection at younger ages and smaller diameters; LDS4 aneurysms typically appear in the fourth decade.
Cervical spine instability, a recognised feature of the receptor-related subtypes, has not yet been reported in TGFB2 patients. GeneReviews lists it for the Loeys-Dietz spectrum as a whole, so the discrepancy is recorded as an open question in discussion lds4_cervical_spine_instability_subtype_status rather than curated as an LDS4 phenotype.
Reduced penetrance is more common in TGFB2 families than in the receptor-related subtypes.
Discrimination requires identification of the causal gene.

Show evidence (2 references)

PMID:29392890 SUPPORT Human Clinical

"For example cervical spine instability has not yet been seen in TGFB2/3 mutations patients, and craniosynostosis has only been reported once in a SMAD3 patient."

Names a concrete feature that separates TGFB2-related disease from the receptor-related Loeys-Dietz subtypes.

PMID:38919319 SUPPORT Human Clinical

"the clinical course somewhat differs depending on the causative gene, and in particular, the risk of dissection is not so high when the causative gene is any of the latter three genes"

States the gene-dependent difference in dissection risk that separates TGFB2 (one of the "latter three" with TGFB3 and SMAD2) from TGFBR1/TGFBR2.

Familial thoracic aortic aneurysm and dissection MONDO:0019625

Overlapping Features Because non-penetrance and minimal systemic features are common in TGFB2 families, LDS4 is regularly ascertained as apparently nonsyndromic familial thoracic aortic disease. TGFB2 was in fact discovered by linkage in two families ascertained exactly that way, and the systemic features were recognised only afterwards.

Distinguishing Features

Nonsyndromic familial TAAD is most often caused by smooth muscle contractile apparatus genes (ACTA2, MYH11, MYLK, PRKG1); LDS4 by TGFB2.
Careful examination for hypertelorism, bifid uvula, high palate, joint hypermobility and skin findings will often reclassify an apparently nonsyndromic TGFB2 family as LDS4.
TGFB2 is a rare cause of familial thoracic aortic disease: only 2 of 276 familial probands in the original screen.

Show evidence (2 references)

PMID:22772371 SUPPORT Human Clinical

"Therefore, TGFB2 mutations were identified in 2 out of 276 probands with familial thoracic aortic disease."

Quantifies how rare TGFB2 is among familial thoracic aortic disease probands, which is why it is usually found only on a gene panel.

PMID:36832261 SUPPORT Human Clinical

"The risk of acute aortic events differs according to the gene involved and to the specific type of mutation."

Establishes that distinguishing LDS4 from other heritable thoracic aortic disease is not a nomenclature exercise - the causal gene changes the event risk and therefore management.

🔬

Clinical Trials

1

NCT05472519 NOT_APPLICABLE COMPLETED

I-LoDiS, a descriptive clinical-biological study of the immune subpopulations affected in Loeys-Dietz syndrome, measuring follicular helper T cells and intracellular phosphorylated SMAD2/3. It is the only registered study addressing the paradox curated in this entry - that an immunosuppressive cytokine pathway produces an atopic phenotype - and it reads out the same pSMAD2/3 signal whose direction is the subject of the tgfb2_signaling_direction_paradox discussion. It is not LDS4-specific: no TGFB2-restricted trial exists, and the registration names TGFBR1/TGFBR2 as the primary genotypes.

Target Phenotypes: Allergic and inflammatory disease predisposition HP:0012393 Asthma HP:0002099

Show evidence (2 references)

clinicaltrials:NCT05472519 SUPPORT Other

"the investigators propose to perform a descriptive clinical-biological study to identify and study the immune subpopulations most impacted by the causative mutations of LDS"

States the study objective, which is the immunological arm of the LDS phenotype curated in this entry.

clinicaltrials:NCT05472519 SUPPORT Other

"The immuno-allergic complications appear paradoxical because of the major immunosuppressive role of this cytokine on lymphoid and myeloid immune lineages."

States the paradox that motivates the trial, the immunological counterpart of the aortic signalling-direction paradox recorded in the discussions.

🧫

Experimental Models

1

TGFB2-KO/+ human iPSC-derived smooth muscle cells and 3D tissue rings IPSC_DERIVED_MODEL

A human, non-animal model of the LDS4 genotype: CRISPR/Cas9-engineered TGFB2KO/+ and TGFB2G276R/+ human iPSC lines differentiated to smooth muscle cells and assembled into three-dimensional tissue ring constructs, alongside TGFBR3KO/KO lines for epistasis. It supplies the mechanistic arm that patient tissue cannot - controlled genotype, isogenic comparison, and a rescue arm (TGFB2 supplementation or genetic correction).

Publication

PMID:40139558

Pathograph links

Impaired Aortic Root Smooth Muscle Cell Differentiation recapitulates fidelity: moderate Reproduces impaired differentiation of second heart field-derived smooth muscle cells under the exact human genotype (TGFB2 haploinsufficiency), with epistasis showing the effect runs through TGFBR3.

Limitations: iPSC-derived smooth muscle cells and engineered tissue rings lack the haemodynamic loading, adventitia and immune compartment of a real aorta, and the differentiation defect has not been demonstrated in patient aortic tissue - so the arm remains an in vitro inference about human disease.

Readouts

Mechanical competence of engineered SMC tissue rings

Direction: RESTORED

Interpretation: The TGFB2G276R/+ mechanical defect was reversed by TGFB2 supplementation or genetic correction, establishing that the deficit is TGFB2 dose dependent and reversible in this system.

Show evidence (1 reference)

PMID:40139558 SUPPORT In Vitro

"a missense TGFB2 variant (TGFB2G276R/+) caused mechanical defects in SMC tissue ring constructs that were rescued by TGFB2 supplementation or genetic correction"

Reports the rescue measurement underlying this readout.

Show evidence (1 reference)

PMID:40139558 SUPPORT In Vitro

"TGFBR3KO/KO prevented the molecular rescue of TGFB2KO/+ by TGFB2 supplementation indicating the involvement of TGFBR3 in TGFB2-mediated SMC differentiation"

The epistasis result that makes this model informative for the TGFBR3-dependent differentiation node.

🐁

Animal Models

1

Tgfb2 heterozygous null mouse (Tgfb2+/-)

The genotype-matched mouse model of LDS4. Heterozygous Tgfb2 null mice develop aortic annulus and aortic root dilation, establishing that loss of a single Tgfb2 allele is sufficient to cause aortic root aneurysm, and their aortas show increased canonical (pSmad2/3) and non-canonical (pErk1/2) signalling - reproducing the human paradox in a system where the genetics are unambiguous. Compound Tgfb2+/-;Fbn1C1039G/+ mice show phenotypic worsening with high Tgfb1 expression, which is the experimental basis for the compensatory-ligand-shift model.

Species

Mouse

Genotype

Tgfb2 heterozygous knockout

Publication

PMID:22772368

Pathograph links

Paradoxical Aortic TGF-beta Signaling Dysregulation recapitulates fidelity: high The heterozygous null genotype matches the human haploinsufficiency mechanism exactly, and the aortic tissue reproduces both the canonical and non-canonical signalling increase seen in patient aorta.

Limitations: Mice do not develop the craniofacial or articular features of LDS4, and the aortic phenotype has been characterised at fixed early timepoints rather than across the fourth-decade-equivalent natural history that defines the human disorder.

Readouts

Aortic pSmad2/3 and pErk1/2 phosphorylation

Direction: INCREASED

Interpretation: Western blot of Tgfb2+/- aorta shows activation of both TGF-beta signalling arms, the model's structural correlate of the human aortic tissue signature.

Show evidence (1 reference)

PMID:29392890 SUPPORT Model Organism

"Western blot of Tgfb2+/− mouse aortas showed a similar increase in phosphorylation of Smad2/3 and Erk1/2, recapitulating the observations in the human aorta"

Reports the measurement and its direction in the haploinsufficient mouse aorta.

Show evidence (1 reference)

PMID:22772368 SUPPORT Model Organism

"haploinsufficient Tgfb2(+/-) mice have aortic root aneurysm and biochemical evidence of increased canonical and noncanonical TGF-β signaling"

Supports treating the heterozygous null mouse as informative for the paradoxical signalling node.

Progressive Aortic Root Dilation recapitulates fidelity: moderate Tgfb2+/- mice develop dilation of the aortic annulus and aortic root, matching the anatomical distribution of human LDS4 aneurysm.

Limitations: Progression to dissection or rupture - the clinical endpoint that matters in patients - is not established in the heterozygous mouse, so the model captures dilation rather than the full natural history.

Readouts

Aortic root and annulus dimension

Direction: INCREASED

Interpretation: Anatomical dilation at the aortic annulus and root in the heterozygous null mouse.

Show evidence (1 reference)

PMID:29392890 SUPPORT Model Organism

"Tgfb2+/− mice showed dilatations of the aortic annulus and aortic root, a pattern similar to that of LDS and MFS patients"

Reports the dimensional readout and its correspondence to the human anatomical pattern.

Show evidence (1 reference)

PMID:29392890 SUPPORT Model Organism

"confirming that loss‐of‐function of one Tgfb2 allele is sufficient to cause aortic root aneurysm"

States the model's central inference - single-allele loss suffices for aortic root aneurysm.

{ }

Source YAML

click to show

name: Loeys-Dietz Syndrome 4
creation_date: "2026-08-18T00:00:00Z"
category: Mendelian
description: >-
  Loeys-Dietz syndrome 4 (LDS4) is the TGFB2-related subtype of the Loeys-Dietz
  spectrum: an autosomal dominant heritable thoracic aortic disease caused by
  heterozygous loss-of-function variants in TGFB2, the gene encoding the
  transforming growth factor beta 2 ligand. It was defined in 2012 by two
  simultaneous reports - Lindsay et al. described heterozygous TGFB2 mutations
  and deletions producing a phenotype within the Loeys-Dietz spectrum, and
  Boileau et al. mapped familial thoracic aortic aneurysm and dissection with
  mild systemic Marfan-like features to the same gene. LDS4 sits at the milder
  end of the Loeys-Dietz spectrum: aortic root aneurysm is the principal
  cardiovascular lesion but typically presents in the fourth decade rather than
  in childhood, dissection is less frequent than in TGFBR1/TGFBR2-related
  disease, and non-penetrance within families is comparatively common, so
  apparently unaffected obligate carriers are recurrently reported. Skeletal and
  articular features - joint hypermobility, scoliosis, pectus deformity,
  arachnodactyly, recurrent hernia, chronic pain - are often the presenting
  complaint and may be the only manifestation. Craniofacial features
  (hypertelorism, bifid uvula, high palate, and, as first reported in the 2018
  mutation update, cleft palate) place the disorder in the Loeys-Dietz rather
  than the Marfan category, while cervical spine instability - characteristic of
  LDS1/LDS2 - has not yet been reported in TGFB2 patients. The defining
  mechanistic paradox of the disorder is that predicted haploinsufficient TGFB2
  alleles produce aortic tissue with increased TGF-beta signalling (nuclear
  pSMAD2, CTGF) and paradoxically increased TGF-beta 2 and TGF-beta 1
  expression, so the proximal defect and the tissue signature run in opposite
  directions.
disease_term:
  preferred_term: Loeys-Dietz syndrome 4
  term:
    id: MONDO:0013897
    label: Loeys-Dietz syndrome 4
synonyms:
- Loeys-Dietz syndrome type 4
- LDS4
- TGFB2 Loeys-Dietz syndrome
- Loeys-Dietz syndrome caused by mutation in TGFB2
classifications:
  harrisons_chapter:
  - classification_value: CARDIOVASCULAR
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0013897
      label: Loeys-Dietz syndrome 4
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO models Loeys-Dietz syndrome 4 as the TGFB2-caused subtype of
      Loeys-Dietz syndrome (MONDO:0018954), asserting TGFB2 (HGNC:11768) as the
      causal gene via RO:0004003 and carrying the OMIM:614816 cross-reference.
      This entry curates exactly that concept.
definitions:
- name: Molecular and clinical diagnosis of LDS4
  definition_type: DIAGNOSTIC_CRITERIA
  description: >-
    The diagnosis of Loeys-Dietz syndrome is established by identification of a
    heterozygous pathogenic variant in one of the six Loeys-Dietz genes in a
    proband with aortic root enlargement, type A dissection, or other
    characteristic clinical features. LDS4 is the designation applied when that
    gene is TGFB2. Because the cardiovascular phenotype in TGFB2 families is
    milder and later-onset than in TGFBR1/TGFBR2 disease, and because
    non-penetrance is comparatively common, molecular testing rather than the
    clinical aortic threshold is frequently what establishes the diagnosis.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      by the identification of a heterozygous pathogenic variant in SMAD2,
      SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2 or biallelic pathogenic variants in
      IPO8 in a proband with aortic root enlargement, type A dissection, other
      characteristic clinical features of LDS, or a family history of an
      established diagnosis of LDS
    explanation: >-
      GeneReviews states the molecular diagnostic criterion for Loeys-Dietz
      syndrome, naming TGFB2 among the causal genes.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      patients with mutations in TGFB2 share clinical manifestations with LDS,
      and are for this reason now diagnosed with LDS type 4 (LDS4)
    explanation: >-
      Establishes that the LDS4 designation is defined by the causal gene being
      TGFB2, which is the concept MONDO:0013897 models.
  - reference: PMID:36832261
    reference_title: "The Role of Genetic Testing in Patients with Heritable Thoracic Aortic Diseases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To date, six subtypes of LDS are currently described.
    explanation: >-
      Confirms the six-subtype molecular partition of Loeys-Dietz syndrome
      within which LDS4 is the TGFB2 subtype.
references:
- reference: PMID:20301312
  title: "Loeys-Dietz Syndrome."
  tags:
  - GeneReviews
- reference: PMID:23102774
  title: "Thoracic aortic-aneurysm and dissection in association with significant mitral valve disease caused by mutations in TGFB2."
- reference: PMID:28544325
  title: "4.7 Mb deletion encompassing TGFB2 associated with features of Loeys-Dietz syndrome and osteoporosis in adulthood."
inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    LDS4 is inherited in an autosomal dominant manner. Heterozygous TGFB2
    loss-of-function variants segregate with thoracic aortic disease in large
    multigenerational pedigrees, and whole-gene deletions at 1q41 produce the
    same phenotype through haploinsufficiency. Penetrance is incomplete and
    expressivity is highly variable even within a single family: reduced
    penetrance is more common in TGFB2 families than in the receptor-related
    Loeys-Dietz subtypes, so an obligate carrier may be entirely unaffected.
    This is the key practical consequence of the genetics - cascade testing,
    not clinical screening alone, is what identifies at-risk relatives.
    Transmission risk follows directly: each child of an affected individual has
    a 50% chance of inheriting the variant, roughly three quarters of Loeys-Dietz
    probands carry a de novo variant while roughly one quarter have an affected
    parent, and once the familial variant is known prenatal and preimplantation
    genetic testing are available.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      LDS caused by a pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1,
      or TGFBR2 is inherited in an autosomal dominant manner.
    explanation: >-
      GeneReviews states autosomal dominant inheritance for the TGFB2-related
      subtype among the other Loeys-Dietz genes.
  - reference: PMID:22772371
    reference_title: "TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These mutations-a frameshift mutation in exon 6 and a nonsense mutation in
      exon 4-segregated with disease with a combined logarithm of odds (LOD)
      score of 7.7.
    explanation: >-
      Quantifies the dominant segregation of TGFB2 loss-of-function alleles with
      thoracic aortic disease in two large unrelated families.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Non‐penetrance seems more common in TGFB2/3 families.
    explanation: >-
      Qualifies the dominant inheritance: penetrance is reduced relative to the
      TGFBR1/2 subtypes, which is why apparently sporadic presentations and
      clinically unaffected obligate carriers recur in TGFB2 families.
  - reference: PMID:41170304
    reference_title: "A Novel Mutation of TGFB2 Gene Responsible of Loeys-Dietz 4 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pedigree analysis highlighted the high clinical variability of LDS
      signs even within the same family.
    explanation: >-
      Documents intrafamilial variable expressivity in a TGFB2 pedigree, the
      companion observation to reduced penetrance.
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Each child of an individual with LDS has a 50% chance of inheriting the
      pathogenic variant and the disorder.
    explanation: >-
      Gives the per-child recurrence risk that follows from autosomal dominant
      transmission, the figure a family is counselled on.
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Approximately 75% of probands diagnosed with LDS have the disorder as the
      result of a de novo pathogenic variant; approximately 25% of individuals
      diagnosed with LDS have an affected parent.
    explanation: >-
      Quantifies the de novo versus inherited split across Loeys-Dietz syndrome.
      Note this is a spectrum-wide figure, not a TGFB2-specific one, and the
      comparatively common non-penetrance in TGFB2 families means an apparently
      de novo presentation in LDS4 warrants parental testing rather than
      parental examination alone.
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      If the LDS-related pathogenic variant(s) have been identified in an
      affected family member, prenatal and preimplantation genetic testing are
      possible.
    explanation: >-
      States the reproductive options that become available once the familial
      variant is known - the practical payoff of molecular rather than clinical
      diagnosis in a subtype with reduced penetrance.
pathophysiology:
- name: TGFB2 Loss-of-Function Variant
  biological_scale: MOLECULAR
  conforms_to: "aortopathy_tgfbeta_dysregulation#Aortic Wall ECM or Contractile Apparatus Defect"
  description: >-
    Heterozygous TGFB2 variants are the genetic trigger of LDS4. The reported
    allelic spectrum is dominated by predicted loss-of-function classes -
    nonsense, frameshift, splice-site and whole- or partial-gene deletion - with
    a minority of missense alleles; deletions at 1q41 encompassing the whole
    gene produce the same phenotype, which is the strongest human argument that
    the mechanism is simple haploinsufficiency rather than a dominant-negative
    protein. A substantial share of the reported variants fall in the
    latency-associated peptide (LAP) domain or the RKKR furin cleavage motif
    required to release the mature TGF-beta 2 cytokine from LAP. Where a
    frameshift escapes nonsense-mediated decay, the mutant transcript is present
    but the proprotein is degraded, so the net effect is still reduced cellular
    TGF-beta 2.
  genes:
  - preferred_term: TGFB2
    term:
      id: hgnc:11768
      label: TGFB2
  evidence:
  - reference: PMID:22772368
    reference_title: "Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report heterozygous mutations or deletions in the gene encoding
      the TGF-β2 ligand for a phenotype within the LDS spectrum
    explanation: >-
      The defining observation for LDS4: heterozygous TGFB2 mutations and
      whole-gene deletions produce a Loeys-Dietz-spectrum phenotype.
  - reference: PMID:22772371
    reference_title: "TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the mutations are predicted to cause haploinsufficiency for TGFB2
    explanation: >-
      States the predicted molecular consequence of the identified alleles.
  - reference: PMID:22772371
    reference_title: "TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These data suggest that although the deleted transcript is expressed, the
      mutant protein is rapidly degraded by an endoplasmic reticulum-associated
      degradation pathway, resulting in decreased cellular levels of wildtype
      TGF-β2.
    explanation: >-
      Explains how a frameshift allele that escapes nonsense-mediated decay
      still yields functional haploinsufficiency - the protein, not the message,
      is lost.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For TGFB2, 23% of mutations are located in the exons coding for the active
      TGF‐β2 cytokine and 28% reside in the RKKR‐motif, a proteolytic cleavage
      site responsible for releasing mature TGF‐β2 from the latency‐associated
      peptide (LAP).
    explanation: >-
      Describes the domain distribution of TGFB2 alleles, including the
      enrichment at the furin cleavage motif needed to liberate the mature
      ligand.
  downstream:
  - target: Reduced TGF-beta 2 Ligand Availability
    description: >-
      Loss of one functional TGFB2 allele halves the cellular supply of mature
      TGF-beta 2 ligand.
- name: Reduced TGF-beta 2 Ligand Availability
  biological_scale: MOLECULAR
  description: >-
    The proximal biochemical consequence of a TGFB2 loss-of-function allele is
    reduced cellular TGF-beta 2 proprotein and mature ligand. In smooth muscle
    cells and dermal fibroblasts from affected family members, TGFB2 transcript
    levels were comparable to control but TGF-beta 2 proprotein was reduced and
    no truncated protein was detectable. Crucially, this reduction is measured in
    peripheral cells and is the opposite of what the diseased aorta shows, which
    is what sets up the disorder's central paradox.
  biological_processes:
  - preferred_term: transforming growth factor beta receptor signaling pathway
    term:
      id: GO:0007179
      label: transforming growth factor beta receptor signaling pathway
    modifier: DECREASED
  cell_types:
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  - preferred_term: dermal fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  evidence:
  - reference: PMID:22772371
    reference_title: "TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      immunoblot analysis of the TGF-β2 proprotein in cellular lysates from
      these cells showed reduced TGF-β2 proprotein levels in the mutant cells
      compared with the wildtype cells and no evidence of the truncated protein
    explanation: >-
      Direct measurement of reduced TGF-beta 2 proprotein in patient-derived
      smooth muscle cells and fibroblasts, with no truncated species - the
      biochemical definition of haploinsufficiency here.
  - reference: PMID:22772371
    reference_title: "TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the initial pathway driving disease is decreased cellular TGF-β2 levels
      leading to a secondary increase in TGF-β2 production in the diseased aorta
    explanation: >-
      States the authors' sequencing of the two directions: cellular loss first,
      aortic overshoot second. This is the causal ordering this node encodes.
  downstream:
  - target: Paradoxical Aortic TGF-beta Signaling Dysregulation
    description: >-
      Reduced cellular TGF-beta 2 provokes a compensatory response in the aortic
      wall that overshoots into excess TGF-beta signalling.
    hypothesis_groups:
    - compensatory_ligand_overshoot
    evidence:
    - reference: PMID:22772371
      reference_title: "TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        aortic tissue from cases paradoxically shows increased TGF-β2
        expression and immunostaining
      explanation: >-
        Establishes the edge: the same haploinsufficient allele that lowers
        cellular ligand raises aortic TGF-beta 2 expression.
  - target: Impaired Aortic Root Smooth Muscle Cell Differentiation
    description: >-
      TGF-beta 2 is required, via TGFBR3, for differentiation of the second
      heart field-derived smooth muscle cells that populate the aortic root.
    hypothesis_groups:
    - tgfbr3_smc_differentiation
- name: Paradoxical Aortic TGF-beta Signaling Dysregulation
  biological_scale: MOLECULAR
  conforms_to: "aortopathy_tgfbeta_dysregulation#TGF-beta Signaling Dysregulation"
  description: >-
    Despite the loss-of-function genetics, aortic wall tissue from TGFB2-variant
    patients shows the same high-TGF-beta tissue signature as the rest of the
    Loeys-Dietz spectrum: increased nuclear phosphorylated SMAD2 in medial
    smooth muscle cells and increased CTGF expression, together with
    paradoxically increased TGF-beta 2 and TGF-beta 1 ligand expression and
    protein. In the Tgfb2 heterozygous mouse both the canonical (pSmad2/3) and
    non-canonical (pErk1/2) arms are activated, so the dysregulation is not
    confined to the SMAD branch. This node is the conserved hub of the
    heritable-aortopathy module, reached here from a ligand rather than a
    receptor lesion.
  biological_processes:
  - preferred_term: SMAD protein signal transduction
    term:
      id: GO:0060395
      label: SMAD protein signal transduction
    modifier: INCREASED
  - preferred_term: ERK1 and ERK2 cascade
    term:
      id: GO:0070371
      label: ERK1 and ERK2 cascade
    modifier: INCREASED
  cell_types:
  - preferred_term: aortic medial smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  evidence:
  - reference: PMID:22772368
    reference_title: "Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      show upregulation of TGF-β signaling in aortic tissue from affected
      individuals
    explanation: >-
      Documents increased TGF-beta signalling in the aortic tissue of TGFB2
      patients.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      increased pSMAD2 and CTGF expression was observed in the aortic media of
      patients with either loss‐of‐function TGFB2 or TGFB3 mutations, further
      confirming the paradoxical observation of increased TGF‐β signaling in
      vivo
    explanation: >-
      Localises the increased canonical signalling and its transcriptional
      output (CTGF) specifically to the aortic media of TGFB2 patients.
  - reference: PMID:27782106
    reference_title: "A missense TGFB2 variant p.(Arg320Cys) causes a paradoxical and striking increase in aortic TGFB1/2 expression."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was striking upregulation of TGFB1 and TGFB2 expression on
      immunofluorescent staining, and western blotting of the aortic tissue from
      the index case
    explanation: >-
      Independent confirmation in a missense-allele pedigree that both TGF-beta
      1 and TGF-beta 2 are up-regulated in the LDS4 aorta.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Western blot of Tgfb2+/− mouse aortas showed a similar increase in
      phosphorylation of Smad2/3 and Erk1/2, recapitulating the observations in
      the human aorta
    explanation: >-
      Shows both canonical and non-canonical arms are activated in the
      haploinsufficient mouse aorta, matching the human tissue signature.
  downstream:
  - target: Aortic Medial Degeneration
    description: >-
      Sustained excess TGF-beta signalling in the media drives elastic fibre
      breakdown and proteoglycan accumulation.
- name: Impaired Aortic Root Smooth Muscle Cell Differentiation
  biological_scale: CELLULAR
  description: >-
    A developmental arm that helps explain why the aneurysm in LDS4 is
    concentrated at the aortic root. In human iPSC-derived smooth muscle cells,
    TGFB2 signals distinctively through TGFBR3 (betaglycan) rather than only the
    canonical type I/II receptors, and both TGFB2 and TGFBR3 are enriched in the
    tunica media of the aortic root specifically. TGFB2 haploinsufficiency and
    TGFB2 neutralisation impair differentiation of second heart field-derived
    smooth muscle cells - the lineage that populates the root - and a missense
    TGFB2 variant produced measurable mechanical defects in engineered smooth
    muscle tissue rings that were rescued by adding back TGFB2. This arm is
    grounded entirely in an in vitro human system; it complements rather than
    replaces the paradoxical-signalling arm.
  biological_processes:
  - preferred_term: smooth muscle cell differentiation
    term:
      id: GO:0051145
      label: smooth muscle cell differentiation
    modifier: DECREASED
  cell_types:
  - preferred_term: second heart field-derived smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  evidence:
  - reference: PMID:40139558
    reference_title: "TGFBR3 dependent mechanism of TGFB2 in smooth muscle cell differentiation and implications for TGFB2-related aortic aneurysm."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      TGFB2 haploinsufficiency (TGFB2KO/+) and TGFB2 neutralization impaired the
      differentiation of second heart field-derived SMCs.
    explanation: >-
      Direct demonstration that TGFB2 haploinsufficiency - the LDS4 genotype -
      impairs differentiation of the smooth muscle lineage that builds the
      aortic root.
  - reference: PMID:40139558
    reference_title: "TGFBR3 dependent mechanism of TGFB2 in smooth muscle cell differentiation and implications for TGFB2-related aortic aneurysm."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Molecular evaluation of different thoracic aorta regions suggested TGFB2
      and TGFBR3 enrichment in the aortic root tunica media.
    explanation: >-
      Provides the regional explanation for root-predominant disease: the
      TGFB2-TGFBR3 axis is enriched exactly where the aneurysm forms.
  downstream:
  - target: Aortic Medial Degeneration
    description: >-
      A structurally deficient root media is more vulnerable to the degenerative
      process.
- name: Aortic Medial Degeneration
  biological_scale: TISSUE
  conforms_to: "aortopathy_tgfbeta_dysregulation#Aortic Medial Degeneration and Wall Weakening"
  description: >-
    The histological lesion of LDS4 is the medial degeneration common to the
    heritable aortopathies: fragmentation and loss of elastic fibres in the
    tunica media with accumulation of proteoglycans, described in both of the
    2012 defining cohorts and independently as cystic medial necrosis in a
    dissected LDS4 aorta. The result is a media that has lost its recoil and
    tensile competence.
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: ABNORMAL
  - preferred_term: elastic fiber assembly
    term:
      id: GO:0048251
      label: elastic fiber assembly
    modifier: DECREASED
  evidence:
  - reference: PMID:22772371
    reference_title: "TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The aortic pathology typical for thoracic aortic disease was found, which
      is characterized by fragmentation and loss of elastin fibers and
      accumulation of proteoglycans in the tunica media
    explanation: >-
      Describes the medial lesion directly in aortic tissue from two TGFB2
      patients.
  - reference: PMID:27782106
    reference_title: "A missense TGFB2 variant p.(Arg320Cys) causes a paradoxical and striking increase in aortic TGFB1/2 expression."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Histologic examination showed fragmentation and disruption of the aortic
      elastic fibers and cystic medial necrosis
    explanation: >-
      Independent histological confirmation in the resected aorta of a
      TGFB2-variant patient who had sustained a type A dissection.
  downstream:
  - target: Progressive Aortic Root Dilation
    description: >-
      A weakened media dilates under normal haemodynamic load.
- name: Progressive Aortic Root Dilation
  biological_scale: ORGANISM
  conforms_to: "aortopathy_tgfbeta_dysregulation#Progressive Aortic Dilation and Aneurysm"
  description: >-
    Aortic root dilation at the sinuses of Valsalva is the principal
    cardiovascular manifestation. In LDS4 it characteristically appears later
    than in the receptor-related subtypes - typically in the fourth decade - and
    progresses more slowly, which is the clinical basis for calling LDS4 the mild
    end of the Loeys-Dietz spectrum. Aneurysm and ectasia elsewhere in the
    arterial tree (iliac, carotid, vertebral, cerebral, pulmonary) and arterial
    tortuosity also occur, so surveillance cannot be limited to
    echocardiography of the root.
  evidence:
  - reference: PMID:25163805
    reference_title: "Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      LDS4 represents the mildest end of the LDS spectrum, since aneurysms are
      usually observed in fourth decade and the progression of the disease is
      slower than in the other forms.
    explanation: >-
      States the characteristic later onset and slower progression that
      distinguish the LDS4 aortic phenotype.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The aortic phenotype in patients with SMAD3 mutations is very similar to
      TGFBR1/2 patients, whereas TGFB2 and TGFB3 cardiovascular features tend to
      be milder, although severe aortic presentation at young age has also been
      observed.
    explanation: >-
      Places the TGFB2 aortic phenotype at the milder end of the spectrum while
      explicitly preserving the exception - severe young-onset disease occurs.
  downstream:
  - target: Aortic Dissection and Rupture
    description: >-
      A dilated, degenerate root can dissect or rupture, though less frequently
      in LDS4 than in the receptor-related subtypes.
- name: Aortic Dissection and Rupture
  biological_scale: ORGANISM
  conforms_to: "aortopathy_tgfbeta_dysregulation#Aortic Dissection and Rupture"
  description: >-
    The lethal endpoint. Type A dissection extending the full length of the
    aorta, dissection of abdominal aortic aneurysm, and sudden death have all
    been reported in TGFB2 pedigrees, and it was the occurrence of dissection and
    death across multiple generations that led to gene identification. Relative
    to LDS1/LDS2, dissection in LDS4 is less frequent, but it is not absent -
    families ascertained through sudden death are on record, and descending
    aortic dissection can occur while root dilation is still relatively mild.
  evidence:
  - reference: PMID:27782106
    reference_title: "A missense TGFB2 variant p.(Arg320Cys) causes a paradoxical and striking increase in aortic TGFB1/2 expression."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A CT scan with contrast showed a Stanford type-A dissection with an
      intimal flap extending the full length of the aorta from the aortic valve
      into both iliac arteries
    explanation: >-
      Documents an extensive type A dissection as the presenting event in a
      TGFB2-variant patient.
  - reference: PMID:41170304
    reference_title: "A Novel Mutation of TGFB2 Gene Responsible of Loeys-Dietz 4 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      responsible of LDS4 in a family with sudden death and vascular lesions
    explanation: >-
      Records sudden death within a TGFB2 pedigree, the reason the milder-end
      characterisation must not be read as benign.
  - reference: PMID:38919319
    reference_title: "Hereditary Aortic Aneurysms and Dissections: Clinical Diagnosis and Genetic Testing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      due care should be paid to the fact that descending aortic dissection can
      occur even if dilatation at the root is relatively mild
    explanation: >-
      The clinically decisive qualifier on the milder-phenotype framing:
      dissection risk in the non-root aorta is not indexed to root diameter.
mechanistic_hypotheses:
- hypothesis_group_id: compensatory_ligand_overshoot
  hypothesis_label: Compensatory ligand overshoot (canonical model of the TGF-beta paradox)
  status: CANONICAL
  description: >-
    The canonical reconciliation of the LDS4 paradox. Loss of one TGFB2 allele
    lowers cellular TGF-beta 2; the aortic wall responds with autocrine and/or
    paracrine compensation - increased expression of TGF-beta 2 itself and a
    shift towards TGF-beta 1 - that overshoots, producing a net high-TGF-beta
    tissue signature (nuclear pSMAD2, CTGF) in the diseased aorta. Under this
    model the sequence is decrease first, secondary increase second, and it is
    the secondary excess that drives medial degeneration. Both 2012 defining
    papers converge on it, and the Tgfb2+/- mouse reproduces the same increase
    in canonical and non-canonical signalling.
  evidence:
  - reference: PMID:22772371
    reference_title: "TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the initial pathway driving disease is decreased cellular TGF-β2 levels
      leading to a secondary increase in TGF-β2 production in the diseased aorta
    explanation: >-
      States the two-step model exactly: cellular decrease first, aortic
      compensatory increase second.
  - reference: PMID:22772368
    reference_title: "Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      these data support the hypothesis that compensatory autocrine and/or
      paracrine events contribute to the pathogenesis of TGF-β-mediated
      vasculopathies
    explanation: >-
      Names the compensatory autocrine/paracrine mechanism this hypothesis
      group encodes, on the strength of the Tgfb2+/- and Fbn1/Tgfb2 double
      mutant mouse data.
- hypothesis_group_id: tgfbr3_smc_differentiation
  hypothesis_label: TGFBR3-dependent aortic root smooth muscle differentiation defect
  status: EMERGING
  description: >-
    An emerging, developmentally framed alternative that does not require the
    paradox to be resolved at all. TGFB2 signal transduction in smooth muscle
    cells is distinctively TGFBR3 (betaglycan)-dependent, and the TGFB2-TGFBR3
    axis is enriched in the aortic root tunica media. Under this model, TGFB2
    haploinsufficiency impairs the differentiation of second heart field-derived
    smooth muscle cells that build the root, yielding a regionally deficient
    media - which would explain both the root-predominant distribution of LDS4
    aneurysm and, through redundancy among the TGF-beta isoforms, its milder
    aggressiveness compared with receptor-gene disease. The evidence is entirely
    from a human iPSC/CRISPR system; it has not been shown in patient aortic
    tissue, so this is recorded as EMERGING rather than as a competitor to the
    canonical model.
  evidence:
  - reference: PMID:40139558
    reference_title: "TGFBR3 dependent mechanism of TGFB2 in smooth muscle cell differentiation and implications for TGFB2-related aortic aneurysm."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      siRNA experiments revealed that TGFB2 distinctively displays TGFBR3
      dependence for signal transduction, an understudied TGFβ receptor in TAAD
    explanation: >-
      Establishes the TGFBR3 dependence that is the distinguishing claim of this
      hypothesis.
  - reference: PMID:40139558
    reference_title: "TGFBR3 dependent mechanism of TGFB2 in smooth muscle cell differentiation and implications for TGFB2-related aortic aneurysm."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      redundant activities of TGFβ isoforms provide implications about the
      milder TAAD aggressiveness of pathogenic TGFB2 variants
    explanation: >-
      Offers the model's explanation for why LDS4 is clinically milder than
      receptor-gene Loeys-Dietz. Marked PARTIAL because it is an inference the
      authors draw from isoform redundancy in vitro, not a measured clinical
      comparison.
discussions:
- discussion_id: tgfb2_signaling_direction_paradox
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    By what mechanism does heterozygous loss of function of TGFB2 produce aortic
    tissue with increased canonical and non-canonical TGF-beta signalling, and
    is that excess the cause of medial degeneration or a marker of it?
  attaches_to:
  - pathophysiology#Paradoxical Aortic TGF-beta Signaling Dysregulation
  rationale: >-
    Every measurement in LDS4 that is made in a peripheral cell shows less
    TGF-beta 2; every measurement made in the diseased aorta shows more
    TGF-beta signalling. Several non-exclusive explanations are on the table -
    relief of a canonical negative-feedback loop driving ligand expression and
    non-canonical overactivation; a shift in isoform usage towards TGF-beta 1; a
    non-cell-autonomous paracrine effect between smooth muscle populations of
    different embryonic origin at the transition zones where aneurysms form; and
    recruitment of angiotensin II or activin signalling. The 2018 mutation
    update states explicitly that the mechanism remains elusive. This is not an
    academic point: it determines whether a TGF-beta-directed therapy should
    augment or suppress signalling, and the observed excess may equally be a
    repair response to matrix damage rather than its cause.
  proposed_experiments:
  - experiment_id: lds4_compartment_matched_signalling
    name: Compartment-matched signalling measurement
    description: >-
      Measure TGF-beta 2 ligand, pSMAD2 and pERK1/2 in aortic media, adventitia
      and dermal fibroblasts from the same TGFB2-variant individuals, to
      establish whether the direction of the signalling change is
      tissue-compartment-specific rather than a whole-organism property.
  - experiment_id: lds4_temporal_ordering_mouse
    name: Temporal ordering in the haploinsufficient mouse
    description: >-
      Determine in Tgfb2+/- mice whether the rise in aortic pSmad2/3 and Erk1/2
      precedes or follows the first detectable elastic fibre fragmentation, to
      discriminate a causal excess from a reparative response.
  evidence:
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although TGFB2 mutations are predicted to result in haploinsufficiency,
      the exact mechanisms on how loss‐of‐function mutations lead to a
      paradoxical activation of TGF‐β signaling remain elusive.
    explanation: >-
      An explicit statement from the field's mutation update that this mechanism
      is unresolved - the definition of the gap recorded here.
- discussion_id: tgfb2_deletion_neurodevelopmental_phenotype
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Is the hypotonia, gross motor delay and speech delay/intellectual disability
    reported in patients with 1q41 deletions encompassing TGFB2 attributable to
    TGFB2 haploinsufficiency itself, or to the neighbouring genes also removed by
    the deletion?
  attaches_to:
  - pathophysiology#TGFB2 Loss-of-Function Variant
  rationale: >-
    Neurodevelopmental abnormalities are not a recognised feature of Loeys-Dietz
    syndrome, yet seven of nine reported patients with pure 1q41 deletions
    involving TGFB2 had hypotonia and gross motor delay and three had speech
    delay and/or intellectual disability. The smallest common deletion contains
    two genes, RRP15 and TGFB2, so the deletion series cannot on its own assign
    the phenotype to TGFB2. This matters directly for how an LDS4 diagnosis is
    counselled: whether a child with a whole-gene deletion carries a
    neurodevelopmental risk that a child with an intragenic TGFB2 point mutation
    does not.
  proposed_experiments:
  - experiment_id: lds4_intragenic_vs_deletion_neurodev
    name: Intragenic-variant neurodevelopmental cohort comparison
    description: >-
      Systematically assess development in a cohort of patients with intragenic
      TGFB2 loss-of-function variants and compare with the 1q41 whole-gene
      deletion series; a neurodevelopmental signal restricted to deletion
      carriers would implicate the contiguous genes rather than TGFB2.
  evidence:
  - reference: PMID:35426477
    reference_title: "Loeys-Dietz syndrome caused by 1q41 deletion including TGFB2 is associated with a neurodevelopmental phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The smallest deletion common to all patients is a 785 kb locus that
      contains two genes: RRP15 and TGFB2.
    explanation: >-
      States the contiguous-gene ambiguity that makes the attribution question
      open.
  - reference: PMID:35426477
    reference_title: "Loeys-Dietz syndrome caused by 1q41 deletion including TGFB2 is associated with a neurodevelopmental phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seven of the nine patients present with some degree of hypotonia and gross
      motor delay, and three of the nine present with speech delay and/or
      intellectual disability (ID).
    explanation: >-
      Quantifies the neurodevelopmental findings in the deletion series that
      prompt the question.
  notes: >-
    The same attribution problem extends beyond neurodevelopment. A 4.7 Mb 1q41
    deletion encompassing TGFB2 has been reported with Loeys-Dietz features
    together with adult-onset osteoporosis (PMID:28544325) - osteoporosis is not
    a recognised feature of LDS4 from intragenic variants either, so the
    deletion series may be accumulating a contiguous-gene phenotype rather than
    an expanded TGFB2 phenotype. That report is indexed as a Letter with no
    abstract, so it is recorded here and as a top-level reference rather than as
    an evidence item; the proposed intragenic-versus-deletion cohort comparison
    should score skeletal density alongside development.
- discussion_id: lds4_cervical_spine_instability_subtype_status
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Does cervical spine malformation and/or instability occur in TGFB2-related
    Loeys-Dietz syndrome, or is it confined to the receptor-related subtypes?
  attaches_to:
  - pathophysiology#Reduced TGF-beta 2 Ligand Availability
  rationale: >-
    The two sources disagree in scope rather than in fact. GeneReviews lists
    cervical spine malformation and/or instability among the defining skeletal
    manifestations of Loeys-Dietz syndrome and recommends orthopaedic follow-up
    and, where necessary, surgical fixation - but that account is written across
    SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, TGFBR2 and IPO8 collectively and makes
    no per-gene assignment. The only TGFB2-specific statement in the literature
    runs the other way: the 2018 mutation update reports that cervical spine
    instability has not yet been seen in TGFB2/TGFB3 patients, and uses that
    absence as one of the features distinguishing the ligand-related from the
    receptor-related subtypes. Because a spectrum-level list cannot establish a
    feature in one subtype while the subtype-specific literature records it as
    unobserved, this manifestation is deliberately NOT curated as an LDS4
    phenotype and no surgical-fixation treatment is curated for it; the
    distinguishing_features block records the negation instead. This is an
    absence of report rather than a demonstrated absence - LDS4 is rare, the
    published series are small, and no study has systematically imaged the
    cervical spine in a TGFB2 cohort - so the question is recorded as open
    rather than closed. The management consequence is real either way: if the
    feature does occur at low frequency in TGFB2 carriers it bears on neck
    positioning and intubation during the prophylactic aortic surgery that
    defines this disorder's care pathway.
  proposed_experiments:
  - experiment_id: lds4_cervical_spine_imaging_cohort
    name: Systematic cervical spine imaging in a TGFB2 cohort
    description: >-
      Perform flexion-extension radiography or cross-sectional cervical spine
      imaging prospectively in a molecularly confirmed TGFB2 cohort, with a
      TGFBR1/TGFBR2 comparison group ascertained the same way, to establish
      whether the reported absence in TGFB2 reflects a genuine genotype
      difference or ascertainment - existing TGFB2 reports are aortic-led and
      largely did not image the cervical spine.
  evidence:
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For example cervical spine instability has not yet been seen in TGFB2/3
      mutations patients, and craniosynostosis has only been reported once in a
      SMAD3 patient.
    explanation: >-
      The TGFB2-specific statement that the feature has not been observed in
      this subtype - the reason it is not curated as an LDS4 phenotype.
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      skeletal manifestations (pectus excavatum or pectus carinatum, scoliosis,
      joint laxity, arachnodactyly, talipes equinovarus, and cervical spine
      malformation and/or instability)
    explanation: >-
      GeneReviews lists the manifestation for Loeys-Dietz syndrome as a whole.
      Marked INDIRECT because the account spans all seven Loeys-Dietz genes and
      makes no per-gene assignment, so it does not establish the feature in the
      TGFB2 subtype.
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Surgical fixation of cervical spine instability may be necessary to
      prevent spinal cord damage.
    explanation: >-
      The management pathway that would follow if the feature were established
      in TGFB2 carriers. Retained here rather than as a curated treatment
      because its indication - the phenotype itself - is not established for
      this subtype.
  notes: >-
    Curation decision, recorded so the reasoning is not lost: the GeneReviews
    skeletal-manifestation and orthopaedic-management sentences were mined
    during review and are preserved above as PARTIAL evidence on this gap
    rather than being promoted to a phenotype and a treatment block, which
    would have contradicted the entry's own description and
    differential_diagnoses. The other seven GeneReviews spectrum-level features
    curated in this entry (allergy, asthma, eczema, eosinophilic esophagitis,
    gastritis, inflammatory bowel disease, pregnancy complications) carry no
    such TGFB2-specific negation and are curated normally.
differential_diagnoses:
- name: Marfan syndrome
  disease_term:
    preferred_term: Marfan syndrome
    term:
      id: MONDO:0007947
      label: Marfan syndrome
  description: >-
    LDS4 is the Loeys-Dietz subtype most easily mistaken for Marfan syndrome:
    both feature aortic root aneurysm at the sinuses of Valsalva, pectus
    deformity, scoliosis, arachnodactyly and striae, and the LDS4 aortic
    phenotype is comparatively mild and late-onset. Patients have carried a
    clinical Marfan diagnosis for years before a TGFB2 lesion was found.
  distinguishing_features:
  - >-
    Marfan syndrome is caused by FBN1 variants; LDS4 by TGFB2 variants or
    whole-gene deletion, so molecular testing - including copy-number analysis,
    since whole-gene deletions are a recognised LDS4 mechanism and are missed by
    sequencing alone - is the definitive discriminator.
  - >-
    Ectopia lentis is characteristic of Marfan syndrome and was not observed in
    the original TGFB2 families.
  - >-
    Hypertelorism, bifid uvula and cleft palate point to the Loeys-Dietz
    spectrum rather than Marfan syndrome.
  - >-
    Widespread arterial tortuosity and aneurysm beyond the aortic root favour
    LDS4; in one reported case it was the appearance of iliac artery ectasia and
    tortuosity at age 38 that prompted revision of a Marfan diagnosis.
  evidence:
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At the age of 38, the appearance of ectasia of the left common iliac
      artery and tortuosity of the iliac arteries suggested the presence of
      LDS4.
    explanation: >-
      Documents the clinical feature that redirected a long-standing Marfan
      diagnosis towards LDS4, and the case in which array-CGH found a whole-gene
      TGFB2 deletion.
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MFS displays ectopia lentis as a distinguishing, characterising feature,
      and thoracic aortic ectasia, aneurysm, dissection, and systemic features as
      manifestations overlapping with LDS4.
    explanation: >-
      States which features separate and which overlap between the two
      disorders.
- name: Loeys-Dietz syndrome (other genetic subtypes)
  disease_term:
    preferred_term: Loeys-Dietz syndrome
    term:
      id: MONDO:0018954
      label: Loeys-Dietz syndrome
  description: >-
    The TGFBR1 (LDS1), TGFBR2 (LDS2), SMAD3 (LDS3), TGFB3 (LDS5), SMAD2 (LDS6)
    and IPO8 subtypes share hypertelorism, bifid uvula/cleft palate, skeletal
    features, arterial tortuosity and aortic aneurysm with LDS4, and are
    distinguished by the causal gene together with severity and a few
    discriminating features.
  distinguishing_features:
  - >-
    The LDS1/LDS2 cardiovascular phenotype is more aggressive, with dissection at
    younger ages and smaller diameters; LDS4 aneurysms typically appear in the
    fourth decade.
  - >-
    Cervical spine instability, a recognised feature of the receptor-related
    subtypes, has not yet been reported in TGFB2 patients. GeneReviews lists it
    for the Loeys-Dietz spectrum as a whole, so the discrepancy is recorded as
    an open question in discussion
    lds4_cervical_spine_instability_subtype_status rather than curated as an
    LDS4 phenotype.
  - >-
    Reduced penetrance is more common in TGFB2 families than in the
    receptor-related subtypes.
  - >-
    Discrimination requires identification of the causal gene.
  evidence:
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For example cervical spine instability has not yet been seen in TGFB2/3
      mutations patients, and craniosynostosis has only been reported once in a
      SMAD3 patient.
    explanation: >-
      Names a concrete feature that separates TGFB2-related disease from the
      receptor-related Loeys-Dietz subtypes.
  - reference: PMID:38919319
    reference_title: "Hereditary Aortic Aneurysms and Dissections: Clinical Diagnosis and Genetic Testing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the clinical course somewhat differs depending on the causative gene, and
      in particular, the risk of dissection is not so high when the causative
      gene is any of the latter three genes
    explanation: >-
      States the gene-dependent difference in dissection risk that separates
      TGFB2 (one of the "latter three" with TGFB3 and SMAD2) from
      TGFBR1/TGFBR2.
- name: Familial thoracic aortic aneurysm and dissection
  disease_term:
    preferred_term: familial thoracic aortic aneurysm and aortic dissection
    term:
      id: MONDO:0019625
      label: familial thoracic aortic aneurysm and aortic dissection
  description: >-
    Because non-penetrance and minimal systemic features are common in TGFB2
    families, LDS4 is regularly ascertained as apparently nonsyndromic familial
    thoracic aortic disease. TGFB2 was in fact discovered by linkage in two
    families ascertained exactly that way, and the systemic features were
    recognised only afterwards.
  distinguishing_features:
  - >-
    Nonsyndromic familial TAAD is most often caused by smooth muscle contractile
    apparatus genes (ACTA2, MYH11, MYLK, PRKG1); LDS4 by TGFB2.
  - >-
    Careful examination for hypertelorism, bifid uvula, high palate, joint
    hypermobility and skin findings will often reclassify an apparently
    nonsyndromic TGFB2 family as LDS4.
  - >-
    TGFB2 is a rare cause of familial thoracic aortic disease: only 2 of 276
    familial probands in the original screen.
  evidence:
  - reference: PMID:22772371
    reference_title: "TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Therefore, TGFB2 mutations were identified in 2 out of 276 probands with
      familial thoracic aortic disease.
    explanation: >-
      Quantifies how rare TGFB2 is among familial thoracic aortic disease
      probands, which is why it is usually found only on a gene panel.
  - reference: PMID:36832261
    reference_title: "The Role of Genetic Testing in Patients with Heritable Thoracic Aortic Diseases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The risk of acute aortic events differs according to the gene involved and
      to the specific type of mutation.
    explanation: >-
      Establishes that distinguishing LDS4 from other heritable thoracic aortic
      disease is not a nomenclature exercise - the causal gene changes the event
      risk and therefore management.
phenotypes:
- category: Cardiovascular
  name: Aortic Root Aneurysm
  description: >-
    Dilation of the aortic root at the sinuses of Valsalva is the principal and
    defining cardiovascular lesion of LDS4, characteristically appearing in the
    fourth decade rather than in childhood.
  phenotype_term:
    preferred_term: Aortic root aneurysm
    term:
      id: HP:0002616
      label: Aortic root aneurysm
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most important clinical finding in LDS patients is dilatation of the
      aortic root at the level of the sinuses of Valsalva, a feature that nearly
      all LDS patients will develop ultimately.
    explanation: >-
      Establishes aortic root dilation as the near-universal cardiovascular
      finding across the Loeys-Dietz spectrum, and supports the VERY_FREQUENT
      band ("nearly all").
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In LDS4 (MIM#614816), unlike MFS, aortic aneurysm involves mainly, but not
      exclusively, the sinus of Valsalva at a later onset than the age of
      thirtyfive
    explanation: >-
      Specifies the LDS4 pattern: sinus of Valsalva predominant, onset after the
      mid-thirties.
- category: Cardiovascular
  name: Aortic Dissection
  description: >-
    Dissection of the thoracic or abdominal aorta, including Stanford type A
    dissection presenting acutely. Less frequent in LDS4 than in the
    receptor-related Loeys-Dietz subtypes, but a documented cause of sudden
    death in TGFB2 families.
  phenotype_term:
    preferred_term: Aortic dissection
    term:
      id: HP:0002647
      label: Aortic dissection
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:27782106
    reference_title: "A missense TGFB2 variant p.(Arg320Cys) causes a paradoxical and striking increase in aortic TGFB1/2 expression."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A CT scan with contrast showed a Stanford type-A dissection with an
      intimal flap extending the full length of the aorta from the aortic valve
      into both iliac arteries
    explanation: >-
      Documents type A dissection in a TGFB2-variant patient.
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The aortic ectasia is relatively mild and has a lower incidence of
      dissection, compared to the other LDS types
    explanation: >-
      Supports the OCCASIONAL rather than FREQUENT band: dissection incidence in
      LDS4 is explicitly lower than in the other Loeys-Dietz subtypes.
- category: Cardiovascular
  name: Arterial Tortuosity
  description: >-
    Tortuosity of the carotid, vertebral, cerebral, iliac and pulmonary arteries.
    Detection requires head-to-pelvis CT or MR angiography with 3D
    reconstruction; echocardiography alone will miss it.
  phenotype_term:
    preferred_term: Arterial tortuosity
    term:
      id: HP:0005116
      label: Arterial tortuosity
  frequency: FREQUENT
  evidence:
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3D reconstruction of images from the head to pelvis is needed to identify
      arterial tortuosity, present in most individuals with a TGFBR1/2, TGFB2,
      or SMAD3 mutation
    explanation: >-
      States that arterial tortuosity is present in most individuals carrying a
      TGFB2 mutation, supporting the FREQUENT band, and names the imaging
      required to detect it.
  - reference: PMID:25163805
    reference_title: "Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Magnetic resonance angiography revealed tortuosity and ectasia of carotid,
      vertebral, cerebral, and segmental pulmonary arteries.
    explanation: >-
      Enumerates the arterial territories involved in a TGFB2 proband who never
      had an aneurysm or dissection - tortuosity was the vascular finding.
- category: Cardiovascular
  name: Mitral Valve Prolapse
  description: >-
    Mitral valve prolapse and mitral regurgitation occur in LDS4. A series of
    six sporadic TGFB2 patients reported a high rate of significant mitral valve
    disease and proposed it as a signature feature of the subtype that should
    itself prompt TGFB2 analysis - a genotype-directing observation rather than
    an incidental valve finding.
  phenotype_term:
    preferred_term: Mitral valve prolapse
    term:
      id: HP:0001634
      label: Mitral valve prolapse
  evidence:
  - reference: PMID:25163805
    reference_title: "Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      dural ectasia, and mitral valve prolapse
    explanation: >-
      Records mitral valve prolapse among the proband's findings.
  - reference: PMID:25163805
    reference_title: "Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      described other 6 sporadic LDS4 patients with TGFB2 mutations, pointing
      out a high rate of mitral valve disease, suggesting that this might be a
      signature feature of the disorder that may direct molecular analysis
    explanation: >-
      Summarises the Renard et al. TGFB2 series (PMID:23102774), which is
      indexed in PubMed as a Letter with no abstract and therefore cannot itself
      supply a verifiable snippet. This sentence carries the substantive claim -
      a high rate of mitral valve disease proposed as a signature feature of
      LDS4 - rather than the five-word fragment it replaces as primary support.
  - reference: PMID:41170304
    reference_title: "A Novel Mutation of TGFB2 Gene Responsible of Loeys-Dietz 4 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      LDS subtypes induce cardiovascular complications, including arterial
      tortuosity, aortic aneurysms and dissections, mitral valve prolapse, and
      arthritis.
    explanation: >-
      Lists mitral valve prolapse among the cardiovascular complications of the
      Loeys-Dietz subtypes, LDS4 included.
- category: Cardiovascular
  name: Bicuspid Aortic Valve
  description: >-
    A two-cusped rather than three-cusped aortic valve. In the differential
    analysis of the eight original TGFB2 families this sits in the group of
    features shared with the Loeys-Dietz subtypes but not with Marfan syndrome,
    so it carries discriminating as well as management weight. It is one of the
    two valve lesions behind the endocarditis-prophylaxis consideration curated
    under treatments. No frequency band is curated - the source is a membership
    list, not a prevalence estimate.
  phenotype_term:
    preferred_term: Bicuspid aortic valve
    term:
      id: HP:0001647
      label: Bicuspid aortic valve
  evidence:
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The second group, shared only with LDSs, includes arterial tortuosity, a
      bicuspid aortic valve, hypertelorism, bifid uvula, thin skin with easy
      bruising, and club feet.
    explanation: >-
      Places bicuspid aortic valve among the features observed across the eight
      original TGFB2 families and shared with the Loeys-Dietz subtypes rather
      than with Marfan syndrome.
- category: Craniofacial
  name: Hypertelorism
  description: >-
    Increased interpupillary distance, one of the craniofacial features that
    places TGFB2-related disease in the Loeys-Dietz rather than the Marfan
    category.
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  evidence:
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      LDS4 is characterised by the presence of hypertelorism, cleft palate
      and/or bifid uvula, with possible ectasia or aneurysms in other arteries.
    explanation: >-
      Names hypertelorism as a characterising craniofacial feature of LDS4
      specifically.
- category: Craniofacial
  name: Bifid Uvula
  description: >-
    Bifid or hypoplastic uvula. Together with hypertelorism this is the
    craniofacial pairing that most reliably signals the Loeys-Dietz spectrum on
    examination of a patient presenting with thoracic aortic disease.
  phenotype_term:
    preferred_term: Bifid uvula
    term:
      id: HP:0000193
      label: Bifid uvula
  evidence:
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The second group, shared only with LDSs, includes arterial tortuosity, a
      bicuspid aortic valve, hypertelorism, bifid uvula, thin skin with easy
      bruising, and club feet.
    explanation: >-
      Assigns bifid uvula to the group of features shared only with Loeys-Dietz,
      as observed across the eight original TGFB2 families.
- category: Craniofacial
  name: Cleft Palate
  description: >-
    Cleft palate was first reported in TGFB2 patients in the 2018 mutation
    update, extending the craniofacial spectrum of LDS4 beyond bifid uvula.
  phenotype_term:
    preferred_term: Cleft palate
    term:
      id: HP:0000175
      label: Cleft palate
  frequency: VERY_RARE
  evidence:
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For the first time, we report on cleft palate in patients with TGFB2
      mutations.
    explanation: >-
      Records the first observation of cleft palate in TGFB2 patients. The
      "first time" framing after a large multicentre series is why the frequency
      is banded VERY_RARE rather than higher.
- category: Craniofacial
  name: High Palate
  description: >-
    A high-arched palate, present with hypoplastic uvula in a TGFB2 proband whose
    presentation was otherwise dominated by articular and skeletal findings.
  phenotype_term:
    preferred_term: High palate
    term:
      id: HP:0000218
      label: High palate
  evidence:
  - reference: PMID:25163805
    reference_title: "Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      showed high palate, hypoplasic uvula, easy bruising, joint hypermobility
    explanation: >-
      Documents high palate in a molecularly confirmed LDS4 proband.
- category: Skeletal
  name: Scoliosis
  description: >-
    Lateral curvature of the spine, one of the skeletal features shared between
    LDS4 and Marfan syndrome. No frequency band is curated: both citations below
    are membership lists that place scoliosis among the features observed in
    TGFB2 patients, which establishes presence but not prevalence, and no series
    reports a denominator for scoliosis in a molecularly confirmed TGFB2 cohort.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the first group common to MFS and LDS including aortic aneurysm, pectus
      deformity, scoliosis, arachnodactyly, and skin striae
    explanation: >-
      Places scoliosis among the features observed across the eight original
      TGFB2 families.
  - reference: PMID:25163805
    reference_title: "Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      joint hypermobility, chronic pain, scoliosis, multiple relapsing hernias
    explanation: >-
      Independent observation of scoliosis in a molecularly confirmed LDS4
      proband.
- category: Skeletal
  name: Pectus Deformity
  description: >-
    Pectus excavatum or carinatum, part of the Marfan-overlapping skeletal group
    in TGFB2 families. The source reports "pectus deformity" without specifying
    which direction, and GeneReviews likewise names both for the Loeys-Dietz
    spectrum, so the claim curated here is the disjunction rather than either
    specific deformity. HPO has no single class for pectus deformity: the
    binding is to the parent Abnormal sternum morphology, which subsumes both
    Pectus excavatum (HP:0000767) and Pectus carinatum (HP:0000768). The more
    specific HP:0000767 was avoided because no cited source states that TGFB2
    patients have excavatum rather than carinatum.
  phenotype_term:
    preferred_term: Pectus deformity (excavatum or carinatum)
    term:
      id: HP:0000766
      label: Abnormal sternum morphology
  evidence:
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the first group common to MFS and LDS including aortic aneurysm, pectus
      deformity, scoliosis, arachnodactyly, and skin striae
    explanation: >-
      Lists pectus deformity among the features observed in the original TGFB2
      families.
- category: Skeletal
  name: Arachnodactyly
  description: >-
    Disproportionately long, slender digits - one of the features that drives the
    clinical confusion with Marfan syndrome.
  phenotype_term:
    preferred_term: Arachnodactyly
    term:
      id: HP:0001166
      label: Arachnodactyly
  evidence:
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the first group common to MFS and LDS including aortic aneurysm, pectus
      deformity, scoliosis, arachnodactyly, and skin striae
    explanation: >-
      Lists arachnodactyly among the Marfan-overlapping features in the original
      TGFB2 families.
- category: Skeletal
  name: Joint Hypermobility
  description: >-
    Generalised joint hypermobility. In the milder LDS4 presentations articular
    and skeletal signs, rather than vascular disease, are what bring the patient
    to attention.
  phenotype_term:
    preferred_term: Joint hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
  frequency: FREQUENT
  evidence:
  - reference: PMID:25163805
    reference_title: "Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      easy bruising, joint hypermobility, chronic pain, scoliosis
    explanation: >-
      Documents joint hypermobility in a molecularly confirmed LDS4 proband.
  - reference: PMID:25163805
    reference_title: "Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      loss-of-function mutations in TGFB2 gene do not always lead to aggressive
      vascular phenotypes and that articular and skeletal signs are prevalent
    explanation: >-
      Supports the FREQUENT band for articular findings in LDS4 and the claim
      that they may dominate the presentation.
- category: Skeletal
  name: Talipes Equinovarus
  description: >-
    Clubfoot, one of the features shared specifically with the Loeys-Dietz
    subtypes rather than with Marfan syndrome.
  phenotype_term:
    preferred_term: Talipes equinovarus
    term:
      id: HP:0001762
      label: Talipes equinovarus
  evidence:
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The second group, shared only with LDSs, includes arterial tortuosity, a
      bicuspid aortic valve, hypertelorism, bifid uvula, thin skin with easy
      bruising, and club feet.
    explanation: >-
      Records clubfoot among the Loeys-Dietz-specific features seen in the
      original TGFB2 families.
- category: Musculoskeletal
  name: Recurrent Hernia
  description: >-
    Multiple relapsing hernias, most often inguinal. Hernias tend to recur after
    repair across the Loeys-Dietz spectrum, which is why supporting mesh is
    recommended.
  phenotype_term:
    preferred_term: Inguinal hernia
    term:
      id: HP:0000023
      label: Inguinal hernia
    temporality: RECURRENT
  evidence:
  - reference: PMID:25163805
    reference_title: "Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      chronic pain, scoliosis, multiple relapsing hernias, dural ectasia
    explanation: >-
      Documents multiple relapsing hernias in a molecularly confirmed LDS4
      proband.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally, osteoarthritis and hernia (mostly inguinal) have been
      frequently observed in all LDS types
    explanation: >-
      Establishes hernia, usually inguinal, as a frequent finding across the
      Loeys-Dietz types including TGFB2.
- category: Musculoskeletal
  name: Osteoarthritis
  description: >-
    Early-onset osteoarthritis, frequently observed across the Loeys-Dietz types.
  phenotype_term:
    preferred_term: Osteoarthritis
    term:
      id: HP:0002758
      label: Osteoarthritis
  evidence:
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally, osteoarthritis and hernia (mostly inguinal) have been
      frequently observed in all LDS types
    explanation: >-
      Records osteoarthritis as a frequent finding across the Loeys-Dietz types
      including TGFB2-related disease.
- category: Cutaneous
  name: Bruising Susceptibility
  description: >-
    Easy bruising with thin, translucent skin - a feature LDS4 shares with the
    other Loeys-Dietz subtypes and with vascular Ehlers-Danlos syndrome.
  phenotype_term:
    preferred_term: Bruising susceptibility
    term:
      id: HP:0000978
      label: Bruising susceptibility
  evidence:
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The second group, shared only with LDSs, includes arterial tortuosity, a
      bicuspid aortic valve, hypertelorism, bifid uvula, thin skin with easy
      bruising, and club feet.
    explanation: >-
      Records thin skin with easy bruising among the Loeys-Dietz-specific
      features in the original TGFB2 families.
- category: Cutaneous
  name: Striae Distensae
  description: >-
    Skin striae, among the features that LDS4 shares with Marfan syndrome.
  phenotype_term:
    preferred_term: Striae distensae
    term:
      id: HP:0001065
      label: Striae distensae
  evidence:
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the first group common to MFS and LDS including aortic aneurysm, pectus
      deformity, scoliosis, arachnodactyly, and skin striae
    explanation: >-
      Lists skin striae among the Marfan-overlapping features in the original
      TGFB2 families.
- category: Neurological
  name: Dural Ectasia
  description: >-
    Widening of the dural sac, a connective-tissue manifestation shared with
    Marfan syndrome and documented in a molecularly confirmed LDS4 proband.
  phenotype_term:
    preferred_term: Dural ectasia
    term:
      id: HP:0100775
      label: Dural ectasia
  evidence:
  - reference: PMID:25163805
    reference_title: "Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      multiple relapsing hernias, dural ectasia, and mitral valve prolapse
    explanation: >-
      Documents dural ectasia in a molecularly confirmed LDS4 proband.
- category: Neurodevelopmental
  name: Hypotonia and Gross Motor Delay
  description: >-
    Reported in the majority of patients carrying 1q41 deletions that encompass
    TGFB2. Neurodevelopmental findings are NOT a recognised feature of
    Loeys-Dietz syndrome generally, and because the smallest common deletion
    also removes RRP15, attribution to TGFB2 itself is unresolved - see the
    tgfb2_deletion_neurodevelopmental_phenotype discussion. Curated here as a
    deletion-associated finding, not as a feature of intragenic TGFB2 disease.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:35426477
    reference_title: "Loeys-Dietz syndrome caused by 1q41 deletion including TGFB2 is associated with a neurodevelopmental phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seven of the nine patients present with some degree of hypotonia and gross
      motor delay, and three of the nine present with speech delay and/or
      intellectual disability (ID).
    explanation: >-
      Quantifies the finding in the 1q41 deletion series. Marked PARTIAL because
      the deletion encompasses a second gene, so the evidence supports the
      association with the deletion but not with TGFB2 haploinsufficiency
      specifically.
  - reference: PMID:35426477
    reference_title: "Loeys-Dietz syndrome caused by 1q41 deletion including TGFB2 is associated with a neurodevelopmental phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neurodevelopmental abnormalities are uncommon in LDS.
    explanation: >-
      Establishes the baseline expectation this finding departs from, which is
      why it is curated with an explicit attribution caveat.
- category: Immunologic
  name: Allergic and Inflammatory Predisposition
  description: >-
    A strong predisposition to allergic and inflammatory disease is part of the
    Loeys-Dietz phenotype, covering reactions to food and environmental
    allergens as well as the organ-specific atopic and gastrointestinal
    manifestations recorded separately below. This is mechanistically striking
    rather than incidental: TGF-beta is an immunosuppressive cytokine, so atopy
    in a TGF-beta-pathway disorder is the immunological counterpart of the
    unresolved aortic signalling-direction paradox recorded in the discussions.
    No TGFB2-specific frequency has been reported, so no frequency band is
    curated.
  phenotype_term:
    preferred_term: Allergic and inflammatory disease predisposition
    term:
      id: HP:0012393
      label: Allergy
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals with LDS can show a strong predisposition for
      allergic/inflammatory disease including asthma, eczema, and reactions to
      food or environmental allergens.
    explanation: >-
      GeneReviews states the allergic/inflammatory predisposition across
      Loeys-Dietz syndrome and enumerates its manifestations.
  - reference: clinicaltrials:NCT05472519
    reference_title: "Immunopathology of Loeys-Dietz Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      immuno-allergic manifestations (asthma, eczema, food allergy,
      eosinophilic esophagitis, chronic inflammatory bowel disease)
    explanation: >-
      An independent enumeration of the same immuno-allergic manifestation set,
      from the registration record of a study designed around it. Marked OTHER
      because a trial registration is a study description, not study evidence.
- category: Respiratory
  name: Asthma
  description: >-
    Asthma occurs as part of the allergic/inflammatory predisposition of
    Loeys-Dietz syndrome rather than as an independent comorbidity. Practically
    it interacts with the cardiovascular management of LDS4, since
    sympathomimetic and decongestant agents are on the agents-to-avoid list.
  phenotype_term:
    preferred_term: Asthma
    term:
      id: HP:0002099
      label: Asthma
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      strong predisposition for allergic/inflammatory disease including asthma
    explanation: >-
      Names asthma among the allergic manifestations of Loeys-Dietz syndrome.
- category: Cutaneous
  name: Eczema
  description: >-
    Eczematous dermatitis, part of the atopic manifestation set. Distinct from
    the connective-tissue skin findings of LDS4 (velvety translucent skin, easy
    bruising, dystrophic scars, striae), which are matrix rather than
    inflammatory phenotypes.
  phenotype_term:
    preferred_term: Eczema
    term:
      id: HP:0000964
      label: Eczematoid dermatitis
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      allergic/inflammatory disease including asthma, eczema, and reactions to
      food or environmental allergens
    explanation: >-
      Names eczema among the allergic manifestations of Loeys-Dietz syndrome.
- category: Gastrointestinal
  name: Eosinophilic Esophagitis
  description: >-
    Eosinophilic infiltration of the oesophagus, part of the increased incidence
    of gastrointestinal inflammation in Loeys-Dietz syndrome. Bound to the
    eosinophilic-infiltration term because HPO has no distinct clinical
    "eosinophilic esophagitis" class; the preferred term keeps the clinical
    diagnosis visible.
  phenotype_term:
    preferred_term: Eosinophilic esophagitis
    term:
      id: HP:0410151
      label: Eosinophilic infiltration of the esophagus
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There is also an increased incidence of gastrointestinal inflammation
      including eosinophilic esophagitis and gastritis or inflammatory bowel
      disease.
    explanation: >-
      States the increased incidence of gastrointestinal inflammation and names
      eosinophilic esophagitis as one of its forms.
- category: Gastrointestinal
  name: Gastritis
  description: >-
    Gastric mucosal inflammation, the second named form of the gastrointestinal
    inflammation associated with Loeys-Dietz syndrome.
  phenotype_term:
    preferred_term: Gastritis
    term:
      id: HP:0005263
      label: Gastritis
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      increased incidence of gastrointestinal inflammation including
      eosinophilic esophagitis and gastritis
    explanation: >-
      Names gastritis among the gastrointestinal inflammatory manifestations.
- category: Gastrointestinal
  name: Inflammatory Bowel Disease
  description: >-
    Inflammatory bowel disease occurs at increased incidence in Loeys-Dietz
    syndrome. Bound to the large-intestine inflammation term, which is the
    closest admissible HPO class; the preferred term retains the clinical
    entity, which is not restricted to the colon.
  phenotype_term:
    preferred_term: Inflammatory bowel disease
    term:
      id: HP:0002037
      label: Inflammation of the large intestine
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      gastrointestinal inflammation including eosinophilic esophagitis and
      gastritis or inflammatory bowel disease
    explanation: >-
      Names inflammatory bowel disease among the gastrointestinal inflammatory
      manifestations.
  - reference: clinicaltrials:NCT05472519
    reference_title: "Immunopathology of Loeys-Dietz Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      eosinophilic esophagitis, chronic inflammatory bowel disease
    explanation: >-
      Independently lists chronic inflammatory bowel disease among the
      immuno-allergic manifestations of Loeys-Dietz syndrome.
- category: Obstetric
  name: Pregnancy-Related Vascular and Uterine Complications
  description: >-
    Pregnancy and the early postpartum period carry increased risk of aortic
    dissection or rupture and of uterine rupture in Loeys-Dietz syndrome. The
    magnitude of that risk is contested and is not established for LDS4
    specifically: the older case-based literature reported catastrophic
    peripartum events, while a systematic review of 522 Loeys-Dietz pregnancies
    put aortic dissection at about 4% and peripartum maternal mortality at about
    1%, and a recent multicentre cohort observed no dissection, uterine rupture
    or maternal death during pregnancy or the first postpartum year. That cohort
    was dominated by TGFBR1, TGFBR2 and SMAD3 genotypes, so it does not settle
    the question for TGFB2. No frequency band is curated for this reason.
  phenotype_term:
    preferred_term: Uterine rupture
    term:
      id: HP:0100718
      label: Uterine rupture
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals with LDS are predisposed to widespread and aggressive arterial
      aneurysms and pregnancy-related complications including uterine rupture
      and death.
    explanation: >-
      GeneReviews states the pregnancy-related risk, naming uterine rupture and
      death.
  - reference: PMID:41718126
    reference_title: "Pregnancy-Related Vascular Outcomes in Loeys-Dietz Syndrome: A Retrospective Cohort Study and Case Series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Another recent systematic review of 522 LDS pregnancies calculated an
      overall aortic dissection rate of about 4% and a maternal mortality rate
      of 1% in the peripartum period
    explanation: >-
      Supplies the quantitative peripartum risk estimate across Loeys-Dietz
      syndrome. Marked PARTIAL because it is spectrum-wide, not TGFB2-specific.
  - reference: PMID:41718126
    reference_title: "Pregnancy-Related Vascular Outcomes in Loeys-Dietz Syndrome: A Retrospective Cohort Study and Case Series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No maternal deaths, aortic dissections, or uterine ruptures occurred
      during gestation or the first postpartum year.
    explanation: >-
      A contemporary multicentre cohort observing no peripartum catastrophe,
      which tempers the older case-based picture. Marked PARTIAL because the
      cohort's commonest genotypes were TGFBR2, TGFBR1 and SMAD3, so it is not
      evidence about TGFB2 specifically.
genetic:
- name: TGFB2
  gene_term:
    preferred_term: TGFB2
    term:
      id: hgnc:11768
      label: TGFB2
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    TGFB2 (1q41) encodes the transforming growth factor beta 2 ligand.
    Heterozygous loss-of-function variants - nonsense, frameshift, splice-site,
    intragenic and whole-gene deletions, and a minority of missense alleles -
    cause LDS4. Thirty distinct variants had been catalogued by the 2018
    mutation update. Reported alleles cluster in the latency-associated peptide
    domain and at the RKKR furin cleavage motif needed to release the mature
    cytokine, and 23% fall in the exons encoding the active cytokine itself.
    Deep-intronic and near-splice-site variants that shift acceptor choice are
    an under-recognised class and are a reason genome rather than panel
    sequencing resolves some families. Contiguous-gene deletions sit at the
    other end of the size range: a 4.7 Mb 1q41 deletion encompassing TGFB2 has
    been reported with Loeys-Dietz features plus adult-onset osteoporosis
    (PMID:28544325), which is why deletion/duplication analysis is not optional
    in LDS4 testing and why the neurodevelopmental attribution question recorded
    in the discussions concerns deletion carriers specifically. That report is
    indexed as a Letter with no abstract in the reference cache, so it is
    carried as a top-level reference and a note rather than as an evidence item
    with a snippet that could not be verified.
  evidence:
  - reference: PMID:22772368
    reference_title: "Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report heterozygous mutations or deletions in the gene encoding
      the TGF-β2 ligand for a phenotype within the LDS spectrum
    explanation: >-
      The primary gene-disease assertion for LDS4.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report 7, 67, 30, and 15 different variants for SMAD2, SMAD3, TGFB2,
      and TGFB3, respectively
    explanation: >-
      Gives the catalogued TGFB2 variant count as of the field's mutation
      update.
  - reference: PMID:39737004
    reference_title: "Novel variant alters splicing of TGFB2 in family with features of Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Molecular validation of the splicing products suggests that the TGFB2
      variants tested impact splicing by reducing efficiency of the canonical
      acceptor in favor of an alternate acceptor within the exon.
    explanation: >-
      Functional characterisation of a near-splice-site intronic TGFB2 variant
      class that panel sequencing would classify as uncertain.
  - reference: PMID:24193348
    reference_title: "A 1-bp duplication in TGFB2 in three family members with a syndromic form of thoracic aortic aneurysm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified the novel heterozygous c.1165dupA mutation in exon 7 of
      TGFB2 in three members of a family, a 51-year-old male, his brother and
      nephew with aortic aneurysms, cervical arterial tortuosity and/or skeletal
      abnormalities as well as craniofacial dysmorphisms.
    explanation: >-
      A worked example of the small-insertion/frameshift allele class in a
      three-member pedigree, extending the variant spectrum beyond the nonsense
      and splice alleles cited above.
  - reference: PMID:24193348
    reference_title: "A 1-bp duplication in TGFB2 in three family members with a syndromic form of thoracic aortic aneurysm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TGFB2 is a rarely mutated gene in patients with syndromic TAAD, and the
      clinical features of our TGFB2 mutation-positive individuals fit in the
      scheme of LDS, rather than MFS-related disorders.
    explanation: >-
      Supports both the haploinsufficiency mechanism curated here and the
      nosological placement of TGFB2 disease within Loeys-Dietz rather than
      Marfan-related disease. The screen was of 88 mutation-negative
      Marfan-like/TAAD probands, so it also speaks to how rare the gene is.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TGFB2 | transforming growth factor beta 2 | hgnc:11768 | Disease-causing germline mutation(s) in"
    explanation: >-
      Orphanet curates TGFB2 as a disease-causing germline gene for Loeys-Dietz
      syndrome.
animal_models:
- name: Tgfb2 heterozygous null mouse (Tgfb2+/-)
  species: Mouse
  genotype: Tgfb2 heterozygous knockout
  publication: PMID:22772368
  description: >-
    The genotype-matched mouse model of LDS4. Heterozygous Tgfb2 null mice
    develop aortic annulus and aortic root dilation, establishing that loss of a
    single Tgfb2 allele is sufficient to cause aortic root aneurysm, and their
    aortas show increased canonical (pSmad2/3) and non-canonical (pErk1/2)
    signalling - reproducing the human paradox in a system where the genetics
    are unambiguous. Compound Tgfb2+/-;Fbn1C1039G/+ mice show phenotypic
    worsening with high Tgfb1 expression, which is the experimental basis for
    the compensatory-ligand-shift model.
  modeled_mechanisms:
  - target: Paradoxical Aortic TGF-beta Signaling Dysregulation
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      The heterozygous null genotype matches the human haploinsufficiency
      mechanism exactly, and the aortic tissue reproduces both the canonical and
      non-canonical signalling increase seen in patient aorta.
    limitations: >-
      Mice do not develop the craniofacial or articular features of LDS4, and
      the aortic phenotype has been characterised at fixed early timepoints
      rather than across the fourth-decade-equivalent natural history that
      defines the human disorder.
    readouts:
    - name: Aortic pSmad2/3 and pErk1/2 phosphorylation
      target: Paradoxical Aortic TGF-beta Signaling Dysregulation
      direction: INCREASED
      interpretation: >-
        Western blot of Tgfb2+/- aorta shows activation of both TGF-beta
        signalling arms, the model's structural correlate of the human aortic
        tissue signature.
      evidence:
      - reference: PMID:29392890
        reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Western blot of Tgfb2+/− mouse aortas showed a similar increase in
          phosphorylation of Smad2/3 and Erk1/2, recapitulating the observations
          in the human aorta
        explanation: >-
          Reports the measurement and its direction in the haploinsufficient
          mouse aorta.
    evidence:
    - reference: PMID:22772368
      reference_title: "Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        haploinsufficient Tgfb2(+/-) mice have aortic root aneurysm and
        biochemical evidence of increased canonical and noncanonical TGF-β
        signaling
      explanation: >-
        Supports treating the heterozygous null mouse as informative for the
        paradoxical signalling node.
  - target: Progressive Aortic Root Dilation
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Tgfb2+/- mice develop dilation of the aortic annulus and aortic root,
      matching the anatomical distribution of human LDS4 aneurysm.
    limitations: >-
      Progression to dissection or rupture - the clinical endpoint that matters
      in patients - is not established in the heterozygous mouse, so the model
      captures dilation rather than the full natural history.
    readouts:
    - name: Aortic root and annulus dimension
      target: Progressive Aortic Root Dilation
      direction: INCREASED
      interpretation: >-
        Anatomical dilation at the aortic annulus and root in the heterozygous
        null mouse.
      evidence:
      - reference: PMID:29392890
        reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Tgfb2+/− mice showed dilatations of the aortic annulus and aortic
          root, a pattern similar to that of LDS and MFS patients
        explanation: >-
          Reports the dimensional readout and its correspondence to the human
          anatomical pattern.
    evidence:
    - reference: PMID:29392890
      reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        confirming that loss‐of‐function of one Tgfb2 allele is sufficient to
        cause aortic root aneurysm
      explanation: >-
        States the model's central inference - single-allele loss suffices for
        aortic root aneurysm.
experimental_models:
- name: TGFB2-KO/+ human iPSC-derived smooth muscle cells and 3D tissue rings
  experimental_model_type: IPSC_DERIVED_MODEL
  description: >-
    A human, non-animal model of the LDS4 genotype: CRISPR/Cas9-engineered
    TGFB2KO/+ and TGFB2G276R/+ human iPSC lines differentiated to smooth muscle
    cells and assembled into three-dimensional tissue ring constructs, alongside
    TGFBR3KO/KO lines for epistasis. It supplies the mechanistic arm that
    patient tissue cannot - controlled genotype, isogenic comparison, and a
    rescue arm (TGFB2 supplementation or genetic correction).
  publication: PMID:40139558
  modeled_mechanisms:
  - target: Impaired Aortic Root Smooth Muscle Cell Differentiation
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reproduces impaired differentiation of second heart field-derived smooth
      muscle cells under the exact human genotype (TGFB2 haploinsufficiency),
      with epistasis showing the effect runs through TGFBR3.
    limitations: >-
      iPSC-derived smooth muscle cells and engineered tissue rings lack the
      haemodynamic loading, adventitia and immune compartment of a real aorta,
      and the differentiation defect has not been demonstrated in patient aortic
      tissue - so the arm remains an in vitro inference about human disease.
    readouts:
    - name: Mechanical competence of engineered SMC tissue rings
      target: Impaired Aortic Root Smooth Muscle Cell Differentiation
      direction: RESTORED
      interpretation: >-
        The TGFB2G276R/+ mechanical defect was reversed by TGFB2 supplementation
        or genetic correction, establishing that the deficit is TGFB2 dose
        dependent and reversible in this system.
      evidence:
      - reference: PMID:40139558
        reference_title: "TGFBR3 dependent mechanism of TGFB2 in smooth muscle cell differentiation and implications for TGFB2-related aortic aneurysm."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          a missense TGFB2 variant (TGFB2G276R/+) caused mechanical defects in
          SMC tissue ring constructs that were rescued by TGFB2 supplementation
          or genetic correction
        explanation: >-
          Reports the rescue measurement underlying this readout.
    evidence:
    - reference: PMID:40139558
      reference_title: "TGFBR3 dependent mechanism of TGFB2 in smooth muscle cell differentiation and implications for TGFB2-related aortic aneurysm."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        TGFBR3KO/KO prevented the molecular rescue of TGFB2KO/+ by TGFB2
        supplementation indicating the involvement of TGFBR3 in TGFB2-mediated
        SMC differentiation
      explanation: >-
        The epistasis result that makes this model informative for the
        TGFBR3-dependent differentiation node.
progression:
- phase: Childhood and adolescence
  age_range: Birth to second decade
  notes: >-
    Craniofacial (hypertelorism, bifid uvula, high palate), skeletal (scoliosis,
    pectus, arachnodactyly, clubfoot) and articular findings may be present from
    early life, and hernias often present in childhood. Aortic disease is
    typically not yet manifest, so a child carrying a familial TGFB2 variant may
    be clinically normal on echocardiography.
  evidence:
  - reference: PMID:25163805
    reference_title: "Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Her 39- and 34-year-old daughters presented with a variable degree of
      musculoskeletal involvement.
    explanation: >-
      Documents musculoskeletal involvement as the manifestation in younger
      TGFB2 variant carriers who had not developed vascular disease. Marked
      PARTIAL because the daughters were adults, so this supports the
      musculoskeletal-first pattern rather than a specifically childhood onset.
- phase: Adulthood - aortic phase
  age_range: Fourth decade onwards
  notes: >-
    Aortic root dilation characteristically becomes apparent in the fourth
    decade and progresses more slowly than in TGFBR1/TGFBR2-related disease.
    This is the window in which surveillance imaging changes management, and it
    is also why a normal echocardiogram in a young carrier gives no reassurance
    about later risk.
  evidence:
  - reference: PMID:25163805
    reference_title: "Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      aneurysms are usually observed in fourth decade and the progression of the
      disease is slower than in the other forms
    explanation: >-
      States the characteristic timing and tempo of the aortic phase in LDS4.
- phase: Complication phase
  age_range: Variable, typically after the fourth decade
  notes: >-
    Dissection, rupture and sudden death are the terminal events. They are less
    frequent than in the receptor-related subtypes but do occur, sometimes as
    the presenting event in a previously undiagnosed family.
  evidence:
  - reference: PMID:41170304
    reference_title: "A Novel Mutation of TGFB2 Gene Responsible of Loeys-Dietz 4 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      responsible of LDS4 in a family with sudden death and vascular lesions
    explanation: >-
      Records sudden death as an outcome in a TGFB2 pedigree.
diagnosis:
- name: Molecular confirmation of a pathogenic TGFB2 variant
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  description: >-
    Sequence analysis of TGFB2, in practice through a multigene heritable
    thoracic aortic disease or connective-tissue panel that also covers TGFBR1,
    TGFBR2, SMAD2, SMAD3, TGFB3 and FBN1, identifies a heterozygous pathogenic
    or likely pathogenic TGFB2 variant. Deletion/duplication analysis is not
    optional in this subtype: whole-gene and contiguous 1q41 deletions are an
    established LDS4 mechanism that sequencing alone misses, and at least one
    reported patient carried a working diagnosis of Marfan syndrome until array
    CGH found the deletion. Testing rather than clinical criteria is frequently
    what establishes the diagnosis, because the cardiovascular phenotype is
    milder and later in onset than in TGFBR1/TGFBR2 disease and non-penetrance
    is comparatively common. A variant of uncertain significance alone does not
    establish the diagnosis; near-splice-site and deep-intronic alleles are a
    recognised source of such results and may need RNA-level characterisation.
  results: >-
    A heterozygous pathogenic or likely pathogenic TGFB2 sequence variant, or a
    deletion encompassing TGFB2, in a compatible clinical or family context
    establishes LDS4.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      by the identification of a heterozygous pathogenic variant in SMAD2,
      SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2 or biallelic pathogenic variants in
      IPO8 in a proband with aortic root enlargement, type A dissection, other
      characteristic clinical features of LDS, or a family history of an
      established diagnosis of LDS
    explanation: >-
      GeneReviews states the molecular diagnostic criterion and names TGFB2 among
      the causal genes.
  - reference: PMID:34680857
    reference_title: "Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Next Generation Sequencing (NGS) analysis, followed by Array-CGH, allowed
      the detection of a novel chromosomal deletion including the entire TGFB2
      gene, confirming not only the clinical suspicion of LDS4
    explanation: >-
      A worked case in which panel sequencing alone was insufficient and copy
      number analysis made the diagnosis - the direct support for requiring
      deletion/duplication coverage in the LDS4 testing strategy.
  - reference: PMID:39737004
    reference_title: "Novel variant alters splicing of TGFB2 in family with features of Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Molecular validation of the splicing products suggests that the TGFB2
      variants tested impact splicing by reducing efficiency of the canonical
      acceptor in favor of an alternate acceptor within the exon.
    explanation: >-
      Shows the RNA-level work that reclassifies a near-splice-site TGFB2
      variant of uncertain significance, the residual-uncertainty branch of this
      testing pathway.
- name: Baseline and serial whole-arterial-tree imaging
  diagnosis_term:
    preferred_term: Diagnostic Imaging Testing
    term:
      id: NCIT:C16502
      label: Diagnostic Imaging Testing
  description: >-
    Echocardiography measures the aortic root and ascending aorta at least
    annually, while MR or CT angiography from head to pelvis at least every other
    year identifies extra-aortic aneurysms, dissections and arterial tortuosity
    that echocardiography cannot see. This is not optional adjunct care in LDS4:
    the disorder's arterial tortuosity and non-root aneurysms are invisible to
    echocardiography, descending aortic dissection can occur while root dilation
    is still mild, and in at least one reported case an extra-aortic finding on
    angiography is what corrected the diagnosis. Imaging frequency is increased
    for genotype, family history, absolute vessel size or growth rate, and during
    pregnancy and the postpartum weeks.
  results: >-
    Aortic root and ascending aortic dimensions plus the presence, location and
    growth rate of aneurysm, dissection or tortuosity anywhere in the arterial
    tree, which together establish vascular extent and set surveillance interval
    and prophylactic repair timing.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Echocardiography to monitor the status of the aortic root and ascending
      aorta (at least annually) and magnetic resonance angiography or
      computerized tomography angiography to assess the entire arterial tree (at
      least every other year)
    explanation: >-
      States the surveillance imaging schedule recommended for Loeys-Dietz
      syndrome.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is essential because aneurysms distant from the aortic root can be
      easily overlooked using echocardiography.
    explanation: >-
      States why whole-arterial-tree imaging rather than echocardiography alone
      is required in TGFB2-related disease.
  - reference: PMID:38919319
    reference_title: "Hereditary Aortic Aneurysms and Dissections: Clinical Diagnosis and Genetic Testing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      careful monitoring is needed for lesions in the branching arteries as well
      as in the aorta
    explanation: >-
      Extends the imaging requirement explicitly to the branch arteries, not the
      aorta alone.
  notes: >-
    Modelled in `diagnosis:` rather than `treatments:` deliberately, following
    the sibling LDS3 entry (Aneurysm-Osteoarthritis_Syndrome): echocardiography
    and MR/CT angiography are diagnostic procedures used for surveillance, not a
    device therapy, and nothing about them acts on a pathophysiology node.
treatments:
- name: Angiotensin Receptor Blocker Therapy
  description: >-
    Angiotensin receptor blockers are used across the Loeys-Dietz spectrum to
    reduce haemodynamic stress on the aortic wall, and losartan additionally
    antagonises TGF-beta signalling - the pathway implicated in the disorder.
    Note that the direction of the underlying signalling defect in LDS4 is
    unresolved (see the tgfb2_signaling_direction_paradox discussion), so the
    rationale for TGF-beta-directed therapy here rests on the observed aortic
    high-TGF-beta tissue signature rather than on a settled model, and there are
    no TGFB2-specific efficacy trials. Critically, angiotensin receptor blockers
    are contraindicated in pregnancy, so the first-line medical therapy of LDS4
    must be reviewed and switched before conception - in a disorder whose
    pregnancy risk is itself elevated and whose diagnosis is often made only
    after childbearing, this is a routine rather than exceptional decision.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: losartan
      term:
        id: CHEBI:6541
        label: losartan
    - preferred_term: angiotensin II receptor antagonist
      term:
        id: NCIT:C66930
        label: Angiotensin II Receptor Antagonist
  target_mechanisms:
  - target: Paradoxical Aortic TGF-beta Signaling Dysregulation
    treatment_effect: INHIBITS
    description: >-
      Losartan reduces haemodynamic wall stress and has TGF-beta-antagonist
      activity, targeting the dysregulated aortic signalling node.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      angiotensin receptor blockers, beta-adrenergic receptor blockers, or other
      medications are used to reduce hemodynamic stress
    explanation: >-
      GeneReviews states the medical management of the cardiovascular features
      of Loeys-Dietz syndrome, of which LDS4 is a subtype.
  - reference: PMID:30725712
    reference_title: "Angiotensin II Receptor Blockers (ARB)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These medications are contraindicated during pregnancy and require caution
      in patients with bilateral renal artery stenosis.
    explanation: >-
      "These medications" are angiotensin II receptor blockers, the class named
      throughout this source. Marked PARTIAL because it is a class-level safety
      statement rather than Loeys-Dietz-specific evidence; it constrains when the
      treatment may be used, not whether it works.
- name: Beta-Blocker Therapy
  description: >-
    Beta-adrenergic receptor blockade to reduce the rate of rise of aortic
    pressure and thereby haemodynamic stress on a dilating aortic root.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: beta-adrenergic antagonist
      term:
        id: NCIT:C29576
        label: Beta-Adrenergic Antagonist
  target_mechanisms:
  - target: Progressive Aortic Root Dilation
    treatment_effect: INHIBITS
    description: >-
      Reducing haemodynamic stress slows the rate of aortic root dilation.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      angiotensin receptor blockers, beta-adrenergic receptor blockers, or other
      medications are used to reduce hemodynamic stress
    explanation: >-
      GeneReviews names beta-adrenergic receptor blockers as part of the medical
      management of Loeys-Dietz cardiovascular disease.
- name: Prophylactic Aortic Root Replacement
  description: >-
    Elective surgical replacement of the aortic root before dissection occurs.
    Across the Loeys-Dietz spectrum the threshold for intervention is lower than
    in Marfan syndrome because dissection can occur at smaller diameters, and
    the vascular disease is not confined to the root. Because dissection risk in
    TGFB2 disease is lower than in TGFBR1/TGFBR2 disease, the most aggressive
    Loeys-Dietz thresholds should be individualised rather than applied
    automatically in LDS4.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Surgical Procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: Aortic Dissection and Rupture
    treatment_effect: INHIBITS
    description: >-
      Replacing the dilated root removes the segment at risk of dissection.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      aortic dissection can occur at smaller aortic diameters and at younger ages
      than observed in Marfan syndrome; vascular disease is not limited to the
      aortic root; angiotensin receptor blockers, beta-adrenergic receptor
      blockers, or other medications are used to reduce hemodynamic stress; and
      aneurysms are amenable to early and aggressive surgical intervention
    explanation: >-
      States the rationale for early and aggressive surgical intervention and
      the lower diameter threshold that applies across Loeys-Dietz syndrome.
  - reference: PMID:38919319
    reference_title: "Hereditary Aortic Aneurysms and Dissections: Clinical Diagnosis and Genetic Testing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the risk of dissection is not so high when the causative gene is any of
      the latter three genes
    explanation: >-
      Supports individualising rather than automatically applying the most
      aggressive Loeys-Dietz surgical threshold in TGFB2 disease. Marked PARTIAL
      because the review states the risk difference, not a TGFB2-specific
      diameter threshold.
- name: Avoidance of Cardiovascular Stressors
  description: >-
    Agents and circumstances to avoid across the Loeys-Dietz spectrum, per
    GeneReviews: contact and competitive sports, isometric exercise, and agents
    that stimulate the cardiovascular system including routine decongestants and
    triptans for migraine.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Contact sports, competitive sports, and isometric exercise; agents that
      stimulate the cardiovascular system including routine use of decongestants
      or triptan medications for the management of migraine headache
    explanation: >-
      The GeneReviews "Agents/circumstances to avoid" list for Loeys-Dietz
      syndrome.
- name: Genetic Counseling and Cascade Testing
  description: >-
    Cascade molecular testing of at-risk relatives is disproportionately
    important in LDS4 because non-penetrance is comparatively common in TGFB2
    families: clinical examination and echocardiography alone will miss carriers
    who have not yet developed - or never develop - aortic disease but who can
    transmit the variant. Copy-number analysis must be included, since
    whole-gene deletions are an established LDS4 mechanism that sequencing alone
    misses.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clarify the genetic status of at-risk relatives of any age either by
      molecular genetic testing
    explanation: >-
      States the GeneReviews recommendation for evaluation of at-risk relatives.
  - reference: PMID:41170304
    reference_title: "A Novel Mutation of TGFB2 Gene Responsible of Loeys-Dietz 4 Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We emphasize the relevance of genetic counseling and molecular analysis to
      identify genetic diseases subtending sudden deaths
    explanation: >-
      Frames genetic counselling and molecular testing as the intervention that
      identifies at-risk relatives in families ascertained through sudden death.
- name: Subacute Bacterial Endocarditis Prophylaxis
  description: >-
    Antibiotic prophylaxis before dental work or other procedures expected to
    cause bacteraemia. Relevant in LDS4 because of the valve disease curated
    here - mitral valve prolapse with regurgitation, bicuspid aortic valve - and
    because prosthetic material is present in anyone who has undergone
    prophylactic aortic root replacement. GeneReviews frames this as a
    consideration rather than a blanket recommendation.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Antibiotic Prophylaxis
    term:
      id: NCIT:C51993
      label: Antibiotic Prophylaxis
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Consider subacute bacterial endocarditis prophylaxis in those undergoing
      dental work or other procedures expected to contaminate the bloodstream
      with bacteria.
    explanation: >-
      GeneReviews states the prophylaxis recommendation and its trigger
      procedures for Loeys-Dietz syndrome.
- name: Hernia Repair with Supporting Mesh
  description: >-
    Surgical hernia repair reinforced with a supporting mesh. The mesh is not a
    surgical preference here but a response to the disease mechanism: the same
    connective-tissue matrix defect that produced the hernia also compromises the
    repair, so recurrence is expected without reinforcement. This pairs directly
    with the recurrent hernia phenotype curated above.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Herniorrhaphy
    term:
      id: NCIT:C168249
      label: Herniorrhaphy
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hernias tend to recur after surgical intervention; a supporting mesh can
      be used during surgical repair to minimize recurrence risk.
    explanation: >-
      GeneReviews states both the recurrence problem and the mesh-reinforced
      repair that addresses it.
- name: Pregnancy Risk Counselling and Intensified Peripartum Aortic Imaging
  description: >-
    Preconception counselling on aortic and uterine rupture risk, review and
    substitution of angiotensin receptor blocker therapy before conception, and
    increased frequency of aortic imaging both during pregnancy and in the weeks
    after delivery. The postpartum arm matters as much as the antenatal one:
    reported Loeys-Dietz peripartum catastrophes cluster in late pregnancy and
    the puerperium, and in a recent cohort the vascular events that did occur
    around pregnancy were postpartum. No LDS4-specific pregnancy outcome rate
    exists, so this is spectrum-level management applied to a subtype whose own
    risk is uncharacterised.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Increased frequency of aortic imaging is recommended, both during
      pregnancy and in the weeks following delivery.
    explanation: >-
      GeneReviews states the peripartum imaging intensification recommended for
      Loeys-Dietz syndrome.
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pregnancy and the postpartum period can be dangerous for women with LDS
      because of increased risk of aortic dissection/rupture and uterine
      rupture.
    explanation: >-
      States the risk that the counselling and intensified imaging are directed
      at.
  - reference: PMID:30725712
    reference_title: "Angiotensin II Receptor Blockers (ARB)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These medications are contraindicated during pregnancy
    explanation: >-
      Supports the medication-review component: the angiotensin receptor blocker
      that is first-line therapy outside pregnancy cannot be continued through
      one. Marked PARTIAL as a class-level safety statement, not
      Loeys-Dietz-specific evidence.
- name: Allergy and Gastrointestinal Inflammation Management
  description: >-
    Standard treatment of allergic and gastrointestinal inflammatory
    complications, with referral to allergy/immunology in severe disease. Two
    LDS-specific caveats make this more than generic atopy care: the
    agents-to-avoid list for the aorta includes routine decongestants, which
    constrains symptomatic management, and the immuno-allergic phenotype is
    itself an active research question rather than settled biology. No
    disease-modifying therapy directed at the allergic arm exists.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Standard treatment for allergic complications with consideration of
      referral to an allergy/immunology specialist in those with severe disease.
    explanation: >-
      GeneReviews states the management approach to the allergic manifestations
      of Loeys-Dietz syndrome.
clinical_trials:
- name: NCT05472519
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    I-LoDiS, a descriptive clinical-biological study of the immune
    subpopulations affected in Loeys-Dietz syndrome, measuring follicular helper
    T cells and intracellular phosphorylated SMAD2/3. It is the only registered
    study addressing the paradox curated in this entry - that an
    immunosuppressive cytokine pathway produces an atopic phenotype - and it
    reads out the same pSMAD2/3 signal whose direction is the subject of the
    tgfb2_signaling_direction_paradox discussion. It is not LDS4-specific: no
    TGFB2-restricted trial exists, and the registration names TGFBR1/TGFBR2 as
    the primary genotypes.
  target_phenotypes:
  - preferred_term: Allergic and inflammatory disease predisposition
    term:
      id: HP:0012393
      label: Allergy
  - preferred_term: Asthma
    term:
      id: HP:0002099
      label: Asthma
  evidence:
  - reference: clinicaltrials:NCT05472519
    reference_title: "Immunopathology of Loeys-Dietz Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      the investigators propose to perform a descriptive clinical-biological
      study to identify and study the immune subpopulations most impacted by the
      causative mutations of LDS
    explanation: >-
      States the study objective, which is the immunological arm of the LDS
      phenotype curated in this entry.
  - reference: clinicaltrials:NCT05472519
    reference_title: "Immunopathology of Loeys-Dietz Syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The immuno-allergic complications appear paradoxical because of the major
      immunosuppressive role of this cytokine on lymphoid and myeloid immune
      lineages.
    explanation: >-
      States the paradox that motivates the trial, the immunological counterpart
      of the aortic signalling-direction paradox recorded in the discussions.
  notes: >-
    Included despite not being TGFB2-restricted because no LDS4-specific trial
    is registered and because its readouts bear directly on two curated open
    questions. Its evidence is marked OTHER throughout: a registration record
    describes a planned study, it is not study evidence, and no results are
    quoted here.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: UNKNOWN
  notes: >-
    No population prevalence has been established for LDS4 specifically. The
    2018 mutation update catalogued 30 distinct TGFB2 variants; the original
    screen found TGFB2 mutations in only 2 of 276 familial thoracic aortic
    disease probands. Loeys-Dietz syndrome as a whole has been quoted at roughly
    1 in 100,000, of which LDS4 is one of six genetic subtypes and not the
    commonest. Because non-penetrance is comparatively common in TGFB2 families,
    ascertained case counts almost certainly understate the number of variant
    carriers.
  evidence:
  - reference: PMID:22772371
    reference_title: "TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Therefore, TGFB2 mutations were identified in 2 out of 276 probands with
      familial thoracic aortic disease.
    explanation: >-
      The only systematic denominator available for TGFB2 among familial
      thoracic aortic disease probands.
  - reference: PMID:39737004
    reference_title: "Novel variant alters splicing of TGFB2 in family with features of Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Loeys-Dietz syndrome (LDS) is a rare connective tissue disorder with a
      prevalence of 1 in 100,000 individuals
    explanation: >-
      Gives the prevalence of Loeys-Dietz syndrome as a whole. Marked PARTIAL
      because it is not specific to the TGFB2 subtype, which is one of six and
      not the commonest.
datasets: []

📚

References & Deep Research

References

3

PMID:20301312

Loeys-Dietz Syndrome.

No top-level findings curated for this source.

PMID:23102774

Thoracic aortic-aneurysm and dissection in association with significant mitral valve disease caused by mutations in TGFB2.

No top-level findings curated for this source.

PMID:28544325

4.7 Mb deletion encompassing TGFB2 associated with features of Loeys-Dietz syndrome and osteoporosis in adulthood.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 21 citations 2026-08-18T09:32:04.106878

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Loeys-Dietz Syndrome 4
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Loeys-Dietz Syndrome 4 covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Loeys–Dietz syndrome type 4: disease-characteristics report

Executive summary and evidence scope

Loeys–Dietz syndrome type 4 (LDS4) is an autosomal-dominant, syndromic heritable thoracic aortic disease caused by heterozygous pathogenic variants in TGFB2, encoding transforming growth factor-β2. The defining risk is progressive aortic-root or other arterial aneurysm, dissection, or rupture, accompanied variably by craniofacial, skeletal, valvular, cutaneous, and dural manifestations. The foundational human study comprised only 15 affected individuals from eight families; consequently, most surveillance and treatment recommendations are extrapolated from pooled LDS or broader heritable thoracic aortic disease (HTAD) evidence rather than TGFB2-specific trials. (lindsay2012lossoffunctionmutationsin pages 1-3)

Evidence labels used below: LDS4-specific means human TGFB2 data; pooled LDS combines molecular subtypes; HTAD extrapolation denotes broader aortopathy evidence. This distinction is critical because recent expert synthesis suggests that TGFB2-associated dissection risk is generally lower than that associated with TGFBR1/TGFBR2 or SMAD3, although major aortic events still occur. (morisaki2024hereditaryaorticaneurysms pages 3-5)

Domain	LDS4-specific finding	Evidence scope	Suggested ontology terms	Key citations
Disease identity	Loeys-Dietz syndrome type 4 (LDS4) is a syndromic heritable thoracic aortic disease within the Loeys-Dietz spectrum caused by TGFB2 pathogenic variants; OMIM 614816 is widely used for LDS4. If a subtype-specific MONDO term is unavailable in the target KB, map cautiously to parent Loeys-Dietz syndrome and annotate subtype in free text.	LDS4-specific for gene/subtype; some identifiers from established reference knowledge	MONDO: parent Loeys-Dietz syndrome if subtype unavailable; MeSH: Loeys-Dietz Syndrome	(lindsay2012lossoffunctionmutationsin pages 1-3, morisaki2024hereditaryaorticaneurysms pages 3-5)
Synonyms	TGFB2-related Loeys-Dietz syndrome; TGFB2-related heritable thoracic aortic disease; syndromic thoracic aortic aneurysm due to TGFB2 loss-of-function.	LDS4-specific	—	(lindsay2012lossoffunctionmutationsin pages 1-3)
Causal gene	TGFB2 (transforming growth factor beta 2) is the established causal gene for LDS4.	LDS4-specific	HGNC: TGFB2	(lindsay2012lossoffunctionmutationsin pages 1-3)
Inheritance	Autosomal dominant inheritance is supported for Loeys-Dietz spectrum disorders and TGFB2-related disease occurs in multigenerational families.	LDS4-specific plus pooled LDS	HPO: Autosomal dominant inheritance	(lindsay2012lossoffunctionmutationsin pages 1-3, morisaki2024hereditaryaorticaneurysms pages 3-5)
Variant mechanism	Founding LDS4 report identified heterozygous loss-of-function mutations or deletions in TGFB2 with paradoxical upregulation of TGF-β signaling in aortic tissue despite reduced ligand dosage. Reported classes include whole/partial deletions, missense, frameshift, in-frame deletion, and nonsense variants. Germline origin is implied.	LDS4-specific	GO: TGF-beta signaling pathway; extracellular matrix organization	(lindsay2012lossoffunctionmutationsin pages 1-3)
Representative pathogenic variants/cohort	Original report described 8 families / 15 patients with variants including del, p.R330C, p.P366H, p.R327W, p.Y369Cfs26, p.A100_Y104del, p.Y99.	LDS4-specific	Sequence variant classes: deletion, missense, frameshift, in-frame deletion, nonsense	(lindsay2012lossoffunctionmutationsin pages 1-3)
Hallmark vascular phenotype	Aortic root aneurysm/dilatation is the major life-threatening feature; supplementary data show aortic root Z-scores roughly 2 to 8.4 and surgical/dissection events including type B dissection at age 42 and valve-sparing root replacement at root diameters around 45 mm, 48 mm, 56 mm in some individuals.	LDS4-specific	HPO: Aortic root dilatation; Thoracic aortic aneurysm; Aortic dissection; Arterial tortuosity	(lindsay2012lossoffunctionmutationsin pages 1-3)
Craniofacial phenotype	Frequent craniofacial features include high-arched palate, retrognathia, downslanting palpebral fissures, and occasional hypertelorism or bifid/broad uvula; craniofacial severity may correlate imperfectly with vascular severity in pooled LDS guidance.	LDS4-specific phenotype table plus pooled LDS interpretation	HPO: High palate; Retrognathia; Downslanted palpebral fissures; Hypertelorism; Bifid uvula	(lindsay2012lossoffunctionmutationsin pages 1-3, morisaki2024hereditaryaorticaneurysms pages 3-5)
Skeletal/connective tissue phenotype	Common systemic findings include pectus deformity, scoliosis, arachnodactyly, club feet, pes planus, and variable generalized hypermobility.	LDS4-specific	HPO: Pectus excavatum/pectus carinatum; Scoliosis; Arachnodactyly; Talipes equinovarus; Pes planus; Joint hypermobility	(lindsay2012lossoffunctionmutationsin pages 1-3)
Cardiac/non-aortic phenotype	Mitral valve abnormalities (MVP, mitral regurgitation, prior mitral surgery), bicuspid aortic valve in some patients, septal defects, pulmonary artery aneurysm, and supraventricular tachycardia were reported.	LDS4-specific	HPO: Mitral valve prolapse; Mitral regurgitation; Bicuspid aortic valve; Atrial septal defect; Ventricular septal defect; Pulmonary artery aneurysm; Supraventricular tachycardia	(lindsay2012lossoffunctionmutationsin pages 1-3)
Skin/other phenotype	Variable striae, thin/soft skin, easy bruising, hernia, keloid or dystrophic scars, livedo reticularis, and occasional dural ectasia/Tarlov cysts were reported.	LDS4-specific	HPO: Cutaneous striae; Thin skin; Easy bruising; Hernia; Dural ectasia; Tarlov cyst	(lindsay2012lossoffunctionmutationsin pages 1-3)
Key anatomy involved	Primary: aortic root, ascending thoracic aorta, descending thoracic aorta, branch arteries. Secondary: heart valves, craniofacial skeleton, skin, dura.	LDS4-specific with pooled LDS extension	UBERON terms to consider: aortic root, thoracic aorta, mitral valve, palate, skin, dura mater	(lindsay2012lossoffunctionmutationsin pages 1-3, morisaki2024hereditaryaorticaneurysms pages 3-5)
Key cell types/processes	Mechanistic literature for LDS/aortopathy implicates vascular smooth muscle cells, fibroblasts/myofibroblasts, and extracellular matrix-producing cells. Core processes include TGF-β signaling dysregulation, SMAD2/3 activation, and extracellular matrix remodeling.	Mostly pooled LDS/aortopathy; not LDS4-exclusive	CL: vascular smooth muscle cell, fibroblast, myofibroblast; GO: TGF-beta receptor signaling pathway, extracellular matrix organization, collagen fibril organization	(lindsay2012lossoffunctionmutationsin pages 1-3, monda2023theroleof pages 6-7)
Diagnostic approach	Diagnosis is established by recognizing syndromic HTAD features and confirming a pathogenic/likely pathogenic TGFB2 variant via molecular testing. In unclear connective-tissue phenotypes, multigene HTAD panels, WES, or WGS are preferred over single-gene testing.	LDS4-specific confirmation; pooled HTAD testing strategy	NCIT/LOINC-style concepts: molecular genetic testing, multigene panel	(monda2023theroleof pages 3-4, morisaki2024hereditaryaorticaneurysms pages 3-5)
Differential diagnosis	Differentiate from other LDS subtypes (TGFBR1/2, SMAD2/3, TGFB3), Marfan syndrome, vascular Ehlers-Danlos syndrome, arterial tortuosity syndrome, and nonsyndromic HTAD.	Pooled LDS/HTAD	—	(monda2023theroleof pages 3-4, morisaki2024hereditaryaorticaneurysms pages 3-5)
Surveillance	Because LDS can affect the entire arterial tree, expert reviews/guidelines recommend whole-body vascular imaging from cerebral circulation to pelvis at diagnosis and repeat imaging based on findings; close monitoring is emphasized, including branch vessels and descending aorta.	Mainly pooled LDS guidance; should be individualized for LDS4 because dissection risk may be lower than TGFBR1/2 but not absent	Imaging concepts: echocardiography, CTA, MRA	(monda2023theroleof pages 6-7, morisaki2024hereditaryaorticaneurysms pages 3-5)
Medical treatment	Pooled LDS guidance recommends starting beta-blocker and/or ARB at diagnosis to reduce aortic growth rate and events; evidence is extrapolated from LDS/Marfan studies rather than LDS4-specific trials.	Pooled LDS evidence	NCIT: Beta-Adrenergic Receptor Blocker; Angiotensin II Receptor Blocker	(monda2023theroleof pages 6-7, monda2023theroleof pages 3-4)
Surgical management	In pooled LDS, surgery thresholds are lower and gene-specific than sporadic aneurysm disease; for TGFBR1/2 high-risk patients, intervention may be considered at root diameter ≥40 mm. For TGFB2, reviews note dissection risk is generally not as high as TGFBR1/2/SMAD3, so thresholds should be individualized rather than automatically applying the most aggressive LDS criteria.	Pooled LDS with specific caution for TGFB2	NCIT: Aortic root replacement; Valve-sparing aortic root replacement; Bentall procedure	(monda2023theroleof pages 6-7, morisaki2024hereditaryaorticaneurysms pages 3-5)
Pregnancy/exercise/lifestyle	Direct LDS4 data are sparse. General heritable aortopathy care supports counseling on pregnancy-related aortic risk, blood pressure control, and individualized exercise guidance. Pediatric pooled LDS/MFS data show reduced physical fitness and suggest tailored exercise programs may help participation and fatigue, but not as a substitute for vascular precautions.	Mostly pooled evidence	—	(warninkkavelaars2024physicalfitnessin pages 1-2)
Epidemiology	LDS overall is rare; one current trial summary cites estimated prevalence 1/25,000–1/100,000 for LDS, but LDS4-specific prevalence/incidence are not established.	Pooled LDS only	—	(NCT05472519 chunk 1)
Prognosis	Prognosis is driven by progression of aortic disease and risk of dissection/rupture. Reviews suggest TGFB2-associated LDS may have a milder dissection risk than TGFBR1/2, yet clinically significant aneurysm, distal dissection, and need for surgery still occur. Long-term LDS4-specific survival statistics remain unavailable.	Mixed: LDS4-specific trend plus pooled HTAD prognosis	—	(morisaki2024hereditaryaorticaneurysms pages 3-5, monda2023theroleof pages 3-4)
Real-world implementation/resources	GenTAC enrolled 3706 patients with genetically triggered thoracic aortic disease, including Loeys-Dietz syndrome, with longitudinal clinical data and biospecimens available via NHLBI BioLINCC; useful for natural history and biomarker work.	Pooled registry infrastructure	—	(NCT01322165 chunk 1)
Current trials relevant to LDS	I-LoDiS / NCT05472519 (completed; n=60) studies immunopathology in LDS and measures TFH cells and intracellular pSMAD2/3. NCT02504853 is an ongoing NIH natural history/genetics protocol including LDS with food allergy/EoE-related phenotypes. Neither is LDS4-specific.	Pooled LDS	—	(NCT05472519 chunk 1, NCT02504853 chunk 1)
Major evidence gaps	No robust LDS4-specific prevalence, penetrance, sex ratio, or survival estimates; limited genotype-phenotype correlations beyond the original families; little direct evidence on protective factors, modifiers, gene-environment interactions, omics biomarkers, pregnancy outcomes, pediatric thresholds, or TGFB2-specific drug response. Most management is extrapolated from pooled LDS/HTAD literature.	Evidence-gap statement	—	(monda2023theroleof pages 3-4, morisaki2024hereditaryaorticaneurysms pages 3-5)

Table: This table summarizes compact, knowledge-base-ready facts for Loeys-Dietz syndrome type 4, distinguishing TGFB2-specific evidence from broader Loeys-Dietz syndrome guidance. It highlights causal genetics, phenotypes, surveillance and treatment practices, trials, and the most important current evidence gaps.

1. Disease information

Definition and identifiers

Preferred name: Loeys–Dietz syndrome type 4.
Synonyms: TGFB2-related Loeys–Dietz syndrome; TGFB2-related syndromic thoracic aortic aneurysm; TGFB2-related HTAD.
OMIM: 614816 is commonly assigned to Loeys–Dietz syndrome 4.
MeSH: D055947, Loeys-Dietz Syndrome, a parent-level term documented in ClinicalTrials.gov indexing. (NCT05472519 chunk 1)
MONDO: a subtype-specific identifier could not be verified from the retrieved primary sources; use the current MONDO parent term for Loeys–Dietz syndrome and retain “type 4/TGFB2-related” as a qualifier rather than guessing an identifier.
ICD-10-CM/ICD-11: no retrieved evidence established a dedicated LDS4 code. Coding generally uses broader congenital connective-tissue/aortic disease categories, supplemented by a molecular diagnosis.
OMIM gene: TGFB2 is conventionally OMIM 190220; gene nomenclature should be validated against the live OMIM/HGNC release before database ingestion.

The evidence is principally aggregated disease-level literature and family cohorts, not EHR-derived population surveillance. The original report nevertheless contains individual-level clinical data for all 15 participants, aged 3–61 years. (lindsay2012lossoffunctionmutationsin pages 1-3)

Foundational primary source: Lindsay et al., Nature Genetics, published July 2012, DOI 10.1038/ng.2349. Its central abstract statement is: “Here, we report heterozygous mutations or deletions in the gene encoding the TGF-β2 ligand for a phenotype within the LDS spectrum and show upregulation of TGF-β signaling in aortic …” (truncated in the retrieved abstract). (lindsay2012lossoffunctionmutationsin pages 1-3)

2. Etiology, risk, protection, and gene–environment interaction

Causal factor

The primary cause is a germline heterozygous pathogenic TGFB2 variant, most often acting through reduced functional TGF-β2 dosage. The founding series included genomic deletions, nonsense, frameshift, in-frame deletion, and missense variants: deletion alleles, p.Arg330Cys, p.Pro366His, p.Arg327Trp, p.Tyr369Cysfs26, p.Ala100_Tyr104del, and p.Tyr99. (lindsay2012lossoffunctionmutationsin pages 1-3)

Risk factors

Genetic: possession of a pathogenic/likely pathogenic TGFB2 allele and an affected parent or family history are the established risks. Each child of a heterozygous affected person has a theoretical 50% transmission probability.
Clinical modifiers: family history of early dissection, rapid aortic growth, widespread arterial disease, and marked systemic manifestations are used in pooled LDS risk stratification, but their quantitative effects in LDS4 have not been established. (monda2023theroleof pages 6-7)
Hemodynamic/environmental: hypertension and activities producing marked blood-pressure surges are biologically plausible aggravators of aortic-wall stress and are managed as modifiable risks in HTAD; no LDS4-specific exposure-effect estimates exist.
Sex, ancestry, age: no reliable LDS4-specific sex ratio, ancestry effect, or age-dependent penetrance estimate is available.

Protective factors

No protective TGFB2 allele or validated environmental protective factor has been identified. Blood-pressure control, avoidance of tobacco, and appropriately restricted rather than absent physical activity are tertiary-prevention practices, not prevention of the inherited disorder itself. Beta-blockers and angiotensin-receptor blockers (ARBs) are used to reduce hemodynamic stress, but direct LDS4 efficacy data are absent. (monda2023theroleof pages 6-7)

Gene–environment interactions

No formal TGFB2-by-smoking, diet, toxin, occupation, or exercise interaction study was found. Pregnancy, uncontrolled hypertension, and high-intensity isometric exertion plausibly interact with genetically weakened aortic tissue by increasing wall stress; these remain clinical extrapolations rather than quantified LDS4 interactions.

3. Phenotypes

The original cohort is too small for stable prevalence estimates; the counts implicit in its table should therefore not be generalized as population frequencies. All manifestations show variable expressivity, and vascular disease is typically chronic and progressive rather than episodic. (lindsay2012lossoffunctionmutationsin pages 1-3)

Cardiovascular and arterial

Aortic-root dilatation/aneurysm—principal clinical sign; reported Z-scores were approximately 2.0–8.4. Onset can be pediatric, while complications may emerge in adulthood. Suggested HPO: Aortic root dilatation, Thoracic aortic aneurysm. (lindsay2012lossoffunctionmutationsin pages 1-3)
Aortic dissection—a type-B dissection occurred at age 42 in the founding series. Suggested HPO: Aortic dissection. (lindsay2012lossoffunctionmutationsin pages 1-3)
Arterial tortuosity/extra-aortic aneurysm—variable; the founding table records arterial tortuosity and a main pulmonary-artery aneurysm. Suggested HPO: Arterial tortuosity, Pulmonary artery aneurysm. (lindsay2012lossoffunctionmutationsin pages 1-3)
Valve/congenital cardiac disease—mitral-valve prolapse or regurgitation, bicuspid aortic valve, atrial or ventricular septal defect, and supraventricular tachycardia occurred in individual patients. Suggested HPO: Mitral valve prolapse, Mitral regurgitation, Bicuspid aortic valve, Atrial septal defect, Ventricular septal defect, Supraventricular tachycardia. (lindsay2012lossoffunctionmutationsin pages 1-3)

Craniofacial and ocular

High-arched palate and retrognathia were common in the original table; downslanting palpebral fissures, hypertelorism, broad/bifid uvula, ptosis, myopia, retinal detachment, and lens opacity were variable. Ectopia lentis is not characteristic in a contemporary gene-comparison table. Suggested HPO terms include High palate, Retrognathia, Downslanted palpebral fissures, Hypertelorism, Bifid uvula, Ptosis, and Myopia. (lindsay2012lossoffunctionmutationsin pages 1-3, morisaki2024hereditaryaorticaneurysms pages 3-5)

Musculoskeletal, skin, and dura

Reported manifestations include tall stature, pectus deformity, scoliosis, arachnodactyly, clubfoot, pes planus, joint hypermobility or dislocation, striae, thin/soft skin, easy bruising, hernia, abnormal scars, livedo reticularis, dural ectasia, and Tarlov cysts. Suggested HPO terms are the correspondingly named concepts: Tall stature, Pectus excavatum/carinatum, Scoliosis, Arachnodactyly, Talipes equinovarus, Pes planus, Generalized joint hypermobility, Cutaneous striae, Thin skin, Easy bruising, Hernia, Dural ectasia, and Tarlov cyst. (lindsay2012lossoffunctionmutationsin pages 1-3)

Allergy, immunity, and quality of life

Allergy, asthma, eczema, food allergy, eosinophilic esophagitis, and inflammatory bowel disease are recognized in pooled LDS, but TGFB2-specific frequencies are unknown. A completed mechanistic study notes increased Treg/Th2 polarization, eosinophils, and total IgE in prior pooled LDS work; it did not enroll TGFB2-defined LDS4 specifically. (NCT05472519 chunk 1)

A 2024 multicenter pediatric study enrolled 42 children aged 6–18 years—36 with Marfan syndrome and only six with pooled LDS. Mean treadmill time-to-exhaustion Z-score was −3.1 (SD 2.9) for the combined group, and self-reported fatigue explained 48%–49% of fitness variance. Its abstract states: “Physical fitness is low in children with MFS or LDS and associated with self-reported fatigue.” These data support quality-of-life and rehabilitation concerns but cannot provide LDS4-specific effect estimates. Published online March 11, 2024; DOI 10.1007/s00431-024-05456-z. (warninkkavelaars2024physicalfitnessin pages 1-2)

4. Genetic and molecular information

Gene and variant interpretation

TGFB2 encodes a secreted TGF-β ligand. The disease is autosomal dominant and germline. The original data strongly support loss of function/haploinsufficiency for deletions and truncating variants, although individual missense alleles require variant-level functional and segregation assessment. (lindsay2012lossoffunctionmutationsin pages 1-3)

For knowledge-base ingestion, each variant should be normalized to the current MANE transcript and classified under ACMG/AMP criteria. A truncating/deletion allele is not automatically pathogenic without checking transcript context, nonsense-mediated decay, population frequency, segregation, and phenotype. Conversely, a VUS must not establish the diagnosis or direct predictive testing.

Pathogenic LDS4 variants are expected to be absent or exceptionally rare in population databases because the disorder is dominant and medically consequential. Exact gnomAD/TOPMed allele counts were not available in the retrieved documents and should be queried per normalized variant.

No reproducible LDS4 modifier gene, protective allele, founder mutation, anticipation mechanism, or disease-specific epigenetic signature has been established. Large deletions involving TGFB2 can cause disease, but LDS4 is not primarily an aneuploidy or recurrent translocation syndrome. (lindsay2012lossoffunctionmutationsin pages 1-3)

5. Environmental and lifestyle information

LDS4 is not caused by toxins, radiation, diet, occupation, smoking, alcohol, or infectious agents. Such exposures can affect general cardiovascular health but have not been shown to initiate LDS4. Practical management emphasizes normal cardiovascular risk reduction, avoidance of smoking/stimulants, blood-pressure control, and individualized limits on heavy isometric or collision exercise. Infectious transmission and zoonotic potential are not applicable.

6. Mechanism and pathophysiology

Causal chain

Upstream genetic trigger: heterozygous TGFB2 loss-of-function reduces normal TGF-β2 ligand production or availability.
Developmental/tissue signaling disturbance: altered ligand balance disrupts homeostatic TGF-β receptor–SMAD signaling in the aortic wall and connective tissues.
Paradoxical downstream signature: despite ligand loss, affected aortic tissue shows increased TGF-β signaling, the central “TGF-β paradox” of LDS. (lindsay2012lossoffunctionmutationsin pages 1-3)
Cellular response: vascular smooth-muscle cells and matrix-producing fibroblast/myofibroblast populations undergo abnormal mechanosensing, differentiation, and extracellular-matrix turnover.
Tissue injury: elastin/collagen architecture and medial integrity deteriorate, producing dilatation, tortuosity, aneurysm, and ultimately dissection or rupture.
Systemic manifestations: analogous developmental and matrix abnormalities affect palate/craniofacial structures, skeleton, skin, valves, and dura.

Suggested annotations are GO: TGF-beta receptor signaling pathway; SMAD protein signal transduction; extracellular matrix organization; collagen fibril organization; blood-vessel morphogenesis; response to mechanical stimulus, and CL: vascular smooth muscle cell, fibroblast, myofibroblast, vascular endothelial cell. These are mechanistically appropriate suggestions, not all directly demonstrated in LDS4.

No LDS4-specific validated metabolomic, lipidomic, proteomic, spatial-transcriptomic, single-cell, CRISPR-screen, or clinical epigenomic signature was identified. Pooled LDS work measures intracellular pSMAD2/3 in lymphocytes, but this is investigational rather than a diagnostic biomarker. (NCT05472519 chunk 1)

7. Anatomical structures affected

Primary organs: aortic root, ascending and descending thoracic aorta, and potentially branch arteries.
Secondary sites: aortic and mitral valves, pulmonary artery, cerebral/neck vasculature, palate and craniofacial skeleton, axial and appendicular skeleton, skin/subcutaneous connective tissue, and dura.
Tissue: arterial tunica media, extracellular matrix, connective tissue, cardiac-valve connective tissue.
Cells: vascular smooth-muscle cells are the principal effector population; fibroblasts/myofibroblasts and endothelial cells are plausible contributors.
Subcellular compartments: secretory pathway/extracellular space for TGFB2 ligand; plasma-membrane receptor complex; cytosol and nucleus for SMAD signaling.

Suggested UBERON concepts include aortic root, thoracic aorta, artery, mitral valve, aortic valve, palate, skin, and dura mater. Lateralization is generally not relevant; vascular disease is segmental/systemic rather than consistently unilateral. (lindsay2012lossoffunctionmutationsin pages 1-3)

8. Temporal development

LDS4 is congenital at the molecular level and lifelong. Craniofacial or skeletal signs may be apparent in infancy or childhood, whereas arterial dilatation can be silent for years. The founding cohort included affected children as young as three and adults up to 61, demonstrating broad age-dependent ascertainment. (lindsay2012lossoffunctionmutationsin pages 1-3)

There is no validated stage system. A practical course is: molecular/systemic predisposition → detectable arterial dilatation/tortuosity → progressive aneurysm → elective repair or acute dissection/rupture → lifelong postoperative surveillance. Remission does not occur; surgery removes a high-risk segment but not the systemic arteriopathy. Critical intervention windows are diagnosis before dissection, detection of accelerated growth, pregnancy planning, and timely prophylactic surgery.

9. Inheritance and population

Inheritance: autosomal dominant.
Penetrance: apparently incomplete and age dependent for individual manifestations; no reliable percentage exists.
Expressivity: markedly variable, even within families.
Anticipation: not established.
Mosaicism: theoretically possible for dominant disorders, but no LDS4-specific germline-mosaicism rate was found.
Founder effects/consanguinity: none established; consanguinity is not a causal requirement.
Carrier frequency: unknown and not meaningful as a recessive “carrier” concept; heterozygotes are at risk.

A ClinicalTrials.gov summary estimates all LDS at approximately 1/25,000–1/100,000, but this is not an LDS4 prevalence estimate. Incidence, geographic distribution, ancestry-specific burden, and male:female ratio for LDS4 remain unknown. (NCT05472519 chunk 1)

10. Diagnostics

Clinical and imaging evaluation

Diagnosis should be suspected with thoracic aortic aneurysm/dissection, arterial tortuosity, a suggestive family history, or combinations of hypertelorism/bifid uvula, pectus deformity, arachnodactyly, clubfoot, thin skin, easy bruising, or dural abnormalities. Baseline evaluation generally includes echocardiography and cross-sectional CT or MR angiography of the arterial tree. Pooled LDS guidance recommends imaging from cerebral circulation through the pelvis at diagnosis because disease may extend beyond the echocardiographic field. (monda2023theroleof pages 6-7)

There is no diagnostic blood chemistry, enzyme assay, metabolite, ECG signature, or biopsy requirement. Histopathology may show medial degeneration but is neither specific nor required.

Molecular testing

Use a validated multigene HTAD panel including TGFB2, TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB3, FBN1, COL3A1, ACTA2, MYH11, MYLK, PRKG1, and other curated genes when phenotype overlaps multiple disorders.
Ensure deletion/duplication analysis, because deletions were present in the founding LDS4 families. (lindsay2012lossoffunctionmutationsin pages 1-3)
Single-gene TGFB2 testing is reasonable when a familial pathogenic variant is known.
WES/WGS can identify sequence variants missed by a limited panel; WGS may improve structural and noncoding detection. Negative sequencing should be followed by review of copy-number coverage and periodic reanalysis.
CMA may detect a larger TGFB2-containing deletion but is less sensitive than sequence testing for small variants. Karyotype, FISH, mitochondrial DNA, and repeat-expansion testing are not routine LDS4 tests.
RNA studies may resolve splice VUS but are adjunctive, not standard first-line diagnostics.

Recent expert analysis emphasizes that early molecular diagnosis enables earlier surveillance and intervention, but pre- and post-test genetic counseling is essential because results affect relatives. Morisaki, Annals of Vascular Diseases, published March 2024; DOI 10.3400/avd.ra.24-00013. (morisaki2024hereditaryaorticaneurysms pages 3-5)

Differential diagnosis and screening

Important alternatives are other molecular LDS types, Marfan syndrome, vascular Ehlers–Danlos syndrome, arterial tortuosity syndrome, Shprintzen–Goldberg syndrome, and nonsyndromic HTAD. Absence of ectopia lentis and the presence of arterial tortuosity or bifid uvula favor LDS over classic Marfan syndrome, but molecular confirmation is required because phenotypes overlap. (morisaki2024hereditaryaorticaneurysms pages 3-5)

Test the familial variant in first-degree relatives (cascade testing) regardless of symptoms. Variant-positive relatives require vascular assessment; variant-negative relatives can usually avoid gene-specific serial surveillance unless family evidence suggests another cause. LDS4 is not part of routine newborn screening.

11. Outcome and prognosis

Aortic dissection or rupture is the principal avoidable cause of death. In the original LDS4 series, one type-B dissection occurred at 42 years, and valve-sparing root repairs occurred around 45, 48, and 56 mm in selected individuals; these observations show clinically important risk but do not define a safe diameter. (lindsay2012lossoffunctionmutationsin pages 1-3)

No credible LDS4-specific 5- or 10-year survival, life expectancy, mortality rate, disability-adjusted life years, or validated prognostic biomarker exists. Contemporary review tables rate TGFB2 disease as having common aortic-root aneurysm but less frequent early dissection than TGFBR1/2 or SMAD3 disease. Distal dissection can nevertheless occur despite relatively mild root enlargement, requiring lifelong whole-aorta/branch-vessel surveillance. (morisaki2024hereditaryaorticaneurysms pages 3-5)

Morbidity includes repeated imaging, medication, prophylactic or emergency surgery, pain, fatigue, exercise restrictions, and reduced school/sport/work participation. The available pediatric fitness results are pooled and too small to quantify LDS4 quality of life. (warninkkavelaars2024physicalfitnessin pages 1-2)

12. Treatment

Medical treatment

There is no cure or approved TGFB2-directed therapy. Pooled LDS/HTAD practice uses:

Beta-blockers to reduce heart rate, contractility, and pulsatile wall stress.
ARBs such as losartan to lower blood pressure and modulate angiotensin/TGF-β pathway cross-talk.
Combination therapy when tolerated, individualized to age, blood pressure, ventricular function, pregnancy status, and adverse effects.

The 2023 review summarizing 2022 ACC/AHA guidance recommends beta-blocker and/or ARB treatment from diagnosis in LDS, but acknowledges that evidence is principally extrapolated rather than based on TGFB2 randomized trials. (monda2023theroleof pages 6-7)

Suggested NCIT intervention concepts: Beta-Adrenergic Receptor Blocker, Angiotensin II Receptor Antagonist, Antihypertensive Therapy. No LDS4 pharmacogenomic dosing rule is established.

Surgery and intervention

Valve-sparing aortic-root replacement is preferred when anatomy and expertise permit; composite root/valve replacement is an alternative. Pooled LDS thresholds must be individualized by gene, diameter indexed to body size, growth rate, family history, extra-aortic features, and surgical expertise. The ≥40-mm threshold quoted for high-risk TGFBR1/TGFBR2 disease should not automatically be transferred to TGFB2, whose natural history appears less aggressive; multidisciplinary gene-informed assessment is essential. (monda2023theroleof pages 6-7, morisaki2024hereditaryaorticaneurysms pages 3-5)

Routine endovascular repair in native connective-tissue aorta is approached cautiously because continued dilatation can compromise landing zones. It may be used selectively in emergencies, peripheral lesions, or where landing zones lie within prior surgical grafts. (monda2023theroleof pages 6-7)

Suggested NCIT terms: Aortic Root Replacement, Valve-Sparing Aortic Root Replacement, Bentall Procedure, Thoracic Endovascular Aortic Repair.

Supportive and advanced therapy

Physical/occupational therapy, orthopedic management, pain/fatigue care, dental/orthodontic care, allergy/gastroenterology care, and psychosocial support should be individualized. Tailored low-to-moderate dynamic exercise may improve fitness, but programs require aortic-specialist clearance. (warninkkavelaars2024physicalfitnessin pages 1-2)

No validated LDS4 gene therapy, CRISPR treatment, cell therapy, ASO/siRNA therapy, or immunotherapy is in clinical use. Activin/rapamycin findings mentioned in pooled cellular work remain preclinical and are not TGFB2 treatment evidence. (monda2023theroleof pages 6-7)

13. Prevention

Primary prevention of the inherited variant is limited to reproductive options: genetic counseling, prenatal diagnosis, and preimplantation genetic testing after a familial pathogenic variant is established. Vaccination does not prevent LDS4.

Secondary prevention consists of cascade genetic testing, presymptomatic echocardiography and head-to-pelvis vascular imaging, blood-pressure monitoring, and early detection of growth. Tertiary prevention includes antihypertensive therapy, avoidance of smoking and extreme exertional blood-pressure surges, pregnancy planning, timely prophylactic surgery, and lifelong postoperative surveillance. (monda2023theroleof pages 6-7)

Pregnancy requires preconception imaging, medication review—ARBs are contraindicated during pregnancy—and coordinated care by maternal-fetal medicine and an aortopathy team. No LDS4-specific pregnancy outcome rate was retrieved.

14. Other species and natural disease

No naturally occurring veterinary disorder confidently equivalent to human TGFB2-related LDS4 was identified. Therefore, breed-specific risk, VBO terms, veterinary prevalence, zoonosis, transmission, and cross-species contagion are not applicable. TGFB2 pathway conservation across vertebrates supports comparative biology, but engineered models should not be mislabeled as naturally occurring disease.

15. Model organisms and experimental systems

The founding work used human aortic tissue and molecular/cellular analyses to demonstrate paradoxically increased TGF-β signaling despite TGFB2 loss. This directly supports the human mechanism but does not by itself establish a fully phenocopying animal model. (lindsay2012lossoffunctionmutationsin pages 1-3)

Potential platforms include heterozygous Tgfb2 loss-of-function mice, patient fibroblasts, induced pluripotent stem-cell–derived vascular smooth-muscle or endothelial cells, and engineered three-dimensional vascular tissues. Their appropriate applications are ligand processing, SMAD signaling, lineage-specific responses, mechanosensing, matrix assembly, and drug screening. Important limitations are developmental lethality with severe Tgfb2 disruption, species-dependent aortic anatomy/hemodynamics, and failure of simple haploinsufficiency models to reproduce the full human age-dependent vascular phenotype. No retrieved study established a standardized LDS4 knock-in model, organoid, or high-throughput CRISPR screen.

Recent developments, trials, and implementation

Genetic testing and gene-specific risk: a 2023 HTAD review emphasized that molecular diagnosis affects surveillance, family screening, and management, while noting the absence of accurate gene-specific adverse-outcome models. Published February 2023; DOI 10.3390/diagnostics13040772. (monda2023theroleof pages 3-4)
Updated 2024 clinical synthesis: contemporary comparison suggests common aortic-root aneurysm but less frequent early dissection in TGFB2 than receptor-associated LDS; it nevertheless stresses distal and branch-vessel monitoring. (morisaki2024hereditaryaorticaneurysms pages 3-5)
I-LoDiS, NCT05472519: completed 2023, actual enrollment 60, nonrandomized blood-sampling study of pooled TGFBR1/TGFBR2 LDS and controls; outcomes included TFH-cell percentage and intracellular pSMAD2/3. It is mechanistic, not a therapeutic or LDS4 trial. ClinicalTrials.gov record. (NCT05472519 chunk 1)
NIH food-allergy natural history, NCT02504853: prospective protocol including LDS, food allergy, atopic dermatitis, and eosinophilic esophagitis; estimated enrollment 1,800. It investigates genetic, cellular, microbial, and biochemical pathways but is not TGFB2-specific. ClinicalTrials.gov record. (NCT02504853 chunk 1)
GenTAC, NCT01322165: NHLBI/NIAMS registry enrolled 3,706 people with genetically triggered thoracic aortic conditions and collected longitudinal data and biospecimens; data/samples are available through NHLBI BioLINCC. It provides real-world infrastructure but did not list TGFB2 among its original named eligibility genes. ClinicalTrials.gov record. (NCT01322165 chunk 1)

Principal evidence gaps and expert interpretation

The most consequential gap is the lack of a large, prospective TGFB2-only natural-history cohort. LDS4-specific penetrance, prevalence, growth rates, diameter-specific dissection risk, pregnancy outcomes, quality of life, drug response, surgical outcomes, and survival remain undefined. Current practice appropriately treats a pathogenic TGFB2 variant as actionable, but the most aggressive thresholds derived from TGFBR1/TGFBR2 disease should not be applied mechanically. Management should combine genotype, personal and family history, serial growth, body size, arterial distribution, and multidisciplinary aortic-team judgment. (monda2023theroleof pages 3-4, morisaki2024hereditaryaorticaneurysms pages 3-5)

Likewise, no validated protective variants, environmental triggers, modifier genes, circulating biomarkers, epigenetic classifiers, multi-omics signatures, or TGFB2-specific advanced therapies were identified. These are genuine “not available” fields for a knowledge-base record rather than evidence of absence.

References

(lindsay2012lossoffunctionmutationsin pages 1-3): Mark E Lindsay, Dorien Schepers, Nikhita Ajit Bolar, Jefferson J Doyle, Elena Gallo, Justyna Fert-Bober, Marlies J E Kempers, Elliot K Fishman, Yichun Chen, Loretha Myers, Djahita Bjeda, Gretchen Oswald, Abdallah F Elias, Howard P Levy, Britt-Marie Anderlid, Margaret H Yang, Ernie M H F Bongers, Janneke Timmermans, Alan C Braverman, Natalie Canham, Geert R Mortier, Han G Brunner, Peter H Byers, Jennifer Van Eyk, Lut Van Laer, Harry C Dietz, and Bart L Loeys. Loss-of-function mutations in tgfb2 cause a syndromic presentation of thoracic aortic aneurysm. Nature Genetics, 44:922-927, Jul 2012. URL: https://doi.org/10.1038/ng.2349, doi:10.1038/ng.2349. This article has 569 citations and is from a highest quality peer-reviewed journal.
(morisaki2024hereditaryaorticaneurysms pages 3-5): Hiroko Morisaki. Hereditary aortic aneurysms and dissections: clinical diagnosis and genetic testing. Annals of Vascular Diseases, 17:128-134, Mar 2024. URL: https://doi.org/10.3400/avd.ra.24-00013, doi:10.3400/avd.ra.24-00013. This article has 7 citations.
(monda2023theroleof pages 6-7): Emanuele Monda, Michele Lioncino, Federica Verrillo, Marta Rubino, Martina Caiazza, Alfredo Mauriello, Natale Guarnaccia, Adelaide Fusco, Annapaola Cirillo, Simona Covino, Ippolita Altobelli, Gaetano Diana, Giuseppe Palmiero, Francesca Dongiglio, Francesco Natale, Arturo Cesaro, Eduardo Bossone, Maria Giovanna Russo, Paolo Calabrò, and Giuseppe Limongelli. The role of genetic testing in patients with heritable thoracic aortic diseases. Diagnostics, 13:772, Feb 2023. URL: https://doi.org/10.3390/diagnostics13040772, doi:10.3390/diagnostics13040772. This article has 23 citations.
(monda2023theroleof pages 3-4): Emanuele Monda, Michele Lioncino, Federica Verrillo, Marta Rubino, Martina Caiazza, Alfredo Mauriello, Natale Guarnaccia, Adelaide Fusco, Annapaola Cirillo, Simona Covino, Ippolita Altobelli, Gaetano Diana, Giuseppe Palmiero, Francesca Dongiglio, Francesco Natale, Arturo Cesaro, Eduardo Bossone, Maria Giovanna Russo, Paolo Calabrò, and Giuseppe Limongelli. The role of genetic testing in patients with heritable thoracic aortic diseases. Diagnostics, 13:772, Feb 2023. URL: https://doi.org/10.3390/diagnostics13040772, doi:10.3390/diagnostics13040772. This article has 23 citations.
(warninkkavelaars2024physicalfitnessin pages 1-2): Jessica Warnink-Kavelaars, Lisanne E. de Koning, Annelies E. van der Hulst, Annemieke I. Buizer, Nicole Poissonnier, Laura E. Wijninga, Leonie A. Menke, Laura Muiño Mosquera, Lies Rombaut, and Raoul H. H. Engelbert. Physical fitness in children with marfan and loeys-dietz syndrome: associations between cardiovascular parameters, systemic manifestations, fatigue, and pain. European Journal of Pediatrics, 183:2421-2429, Mar 2024. URL: https://doi.org/10.1007/s00431-024-05456-z, doi:10.1007/s00431-024-05456-z. This article has 4 citations and is from a peer-reviewed journal.
(NCT05472519 chunk 1): Immunopathology of Loeys-Dietz Syndrome. Hospices Civils de Lyon. 2022. ClinicalTrials.gov Identifier: NCT05472519
(NCT01322165 chunk 1): National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions. National Heart, Lung, and Blood Institute (NHLBI). 2007. ClinicalTrials.gov Identifier: NCT01322165
(NCT02504853 chunk 1): Natural History and Genetics of Food Allergy and Related Conditions. National Institute of Allergy and Infectious Diseases (NIAID). 2015. ClinicalTrials.gov Identifier: NCT02504853

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	4
Resolved	4
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	4
On topic	2
Off topic	0

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Definitions

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Progression

Prevalence

Differential Diagnoses

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Loeys–Dietz syndrome type 4: disease-characteristics report

Executive summary and evidence scope

1. Disease information

Definition and identifiers

2. Etiology, risk, protection, and gene–environment interaction

Causal factor

Risk factors

Protective factors

Gene–environment interactions

3. Phenotypes

Cardiovascular and arterial

Craniofacial and ocular

Musculoskeletal, skin, and dura

Allergy, immunity, and quality of life

4. Genetic and molecular information

Gene and variant interpretation

5. Environmental and lifestyle information

6. Mechanism and pathophysiology

Causal chain

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Clinical and imaging evaluation

Molecular testing

Differential diagnosis and screening

11. Outcome and prognosis

12. Treatment

Medical treatment

Surgery and intervention

Supportive and advanced therapy

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Recent developments, trials, and implementation

Principal evidence gaps and expert interpretation